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Abstract
By
Mohamed Ayed

Advisor: Lei Xie, Ph.D
Computational prediction of a phenotypic response upon the chemical perturbation on a
biological system plays an important role in drug discovery and many other applications.
Chemical fingerprints derived from chemical structures are a widely used feature to build
machine learning models. However, the fingerprints ignore the biological context, thus, they
suffer from several problems such as the activity cliff and curse of dimensionality.
Fundamentally, the chemical modulation of biological activities is a multi-scale process. It is the
genome-wide chemical-target interactions that modulate chemical phenotypic responses. Thus,
the genome-scale chemical-target interaction profile will more directly correlate with in
vitro and in vivo activities than the chemical structure. Nevertheless, the scope of direct
application of the chemical-target interaction profile is limited due to the severe incompleteness,
bias, and noisiness of bioassay data.

To address the aforementioned problems, we developed two new chemical and protein
representation methods in this thesis. The first one is a Latent Target Interaction Profile (LTIP).
LTIP embeds chemicals into a low dimensional continuous latent space that represents
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genome-scale chemical-target interactions. Subsequently, LTIP can be used as a feature to build
machine learning models. Using the drug sensitivity of cancer cell lines as a benchmark, we have
shown that the LTIP robustly outperforms chemical fingerprints regardless of machine learning
algorithms. Moreover, the LTIP is complementary to the chemical fingerprints. We can combine
LTIP with other fingerprints to further improve the performance of bioactivity prediction.
We also developed a new protein sequence embedding method Distilled Sequence Alignment
Embedding (DISAE) to represent proteins. We compared CGKronRLS to other machine
learning algorithms including Random Forest and XGBoost for predicting drug-target
interactions. We show how the resultant protein deep representations can be used to predict
novel drug-protein pairs interactions which can improve drug safety and open many avenues for
drug repurposing.
Our results demonstrate the potential of LTIP in particular and multi-scale modeling in general in
predictive modeling of chemical modulation of biological activities. It also shows the predictive
power of DISAE which can further be improved through deep learning models.
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Chapter 1.
Introduction

The tremendous advances in computational techniques have reflected extensively on drug
discovery, toxicology, environmental science, and other scientific fields. For example, machine
learning has reduced the time and cost of testing chemical compounds in vitro and in vivo by
identifying chemical structures that can modulate desired or unwanted biological activities. Two
of the applications of in silico methods are virtual screening and drug-repurposing. Virtual
screening has accelerated the discovery of chemical structures that will possibly bind to a
biological target. In addition, it has significantly reduced the drug target and chemical structure
space to a manageable width.
On the other hand, reusing the already known drugs to remedy other diseases has greatly
benefited from the latest computation advances. Similar chemicals molecules structures will
most probably have the same biological effect and chemical activity when applied to target sites.
Statistical machine learning algorithms are widely applied to search the large molecules'
databases for such possible structural similarities.

It is critical to select relevant molecular features of chemicals for training a machine learning
model of bioactivities. Chemical fingerprints have provided an easy and quick method to
represent the molecules as a vector of binary bits that denote the existence or absence of internal
substructures or functional groups. Quantitative Structure-Activity Relationship (QSAR) and
virtual screening computational models can use the resultant fingerprint representation. The
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conventional methods for QSAR and virtual screening are either ligand-based or target-based.
The premise of the ligand-based method is that similar chemical structures will probably have
the same biological activity. Therefore, chemical compounds need to be represented in some
form so that the assessment of their similarities can be measured. The Tanimoto coefficient
(a.k.a. Jaccard Index) measures the similarity between binary fingerprints. However, the
Tanimoto coefficient loses its quantification power as the dimension of the vector gets higher,
suggesting the need to use other similarity coefficients. Fundamentally, the chemical space has
activity cliffs where a slight change in structure may lead to substantially different bioactivities
since the bioactivity depends on both the structure of the molecule and its biological targets in a
cellular context. The target-based QSAR and virtual screening such as protein-ligand docking
have been widely used in drug discovery when the target information of chemical is available.
However, there is a gap in the target-based method: the binding affinity of a single target may
not correlate with in vitro or in vivo activity.

If one has an unknown tumor cell genes profile with unknown drugs' sensitivities data, one can
predict how it will react to different drugs based on how "much" it is, similar to the known
supervised data in hand: in other words, similarity learning. Defining a similarity metric is
crucial in the drug potency evaluation and drug discovery process. We need a measure of
similarities between drugs to see if they can bind to the same target or not. In fingerprints, each
attribute is binary such that each bit represents the absence or presence of a characteristic, thus, it
is better to determine the similarity via the overlap, or intersection, of the sets. It is tough to build
one model that will fit all situations since data comes from different sources. Quantifying the
level of similarity or dissimilarity is crucial in QSAR model performance.
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Fundamentally, the chemical modulation of biological activity is a complex process. As shown
in Figure 1, it starts from the interaction of chemicals with genome-wide macromolecular targets
in the cell. A chemical not only binds to its primary target (on-target) but also often interacts
with unexpected off-targets. Both on-targets and off-targets collectively mediate phenotypic
responses through biological networks. Thus, the introduction of a genome-wide target binding
profile, in principle, will fill in the gap between the chemical structure and biological activity and
potentially increase the power of predictive modeling of the bioactivity modulated by the
chemical.
In practice, drugs designed for specific protein targets have side effects. Side effects result from
the fact that other off-targets are also affected. It is crucial to understand how the biological
cellular network responds to individual drugs, resulting in an accurate representation of drugs,
leading to accurate QSAR predictions. Identifying unexpected drug efficacy and side effects will
lead to better patients' treatments and safety. it will also enhance drug repurposing, allowing the
treatment of other diseases with drugs. Many methods already exist which link drugs to their
phenotypes. Despite these promising results, they suffered from many disadvantages like being
biased and low prediction results.

Intuitively, a chemical can be represented by its known target binding profile in the form of
affinity fingerprints , which can then be used as a feature for machine learning. However,
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Figure 1 General Overview
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Observed chemical-target interactions are highly noisy, sparse, and biased. Only a tiny portion of
chemicals have the full spectrum of binding affinity to the same set of biological targets in the
chemical genomics databases. It is infeasible to carry out multiple experimental bioassays for
tens of millions of chemicals in the same condition to obtain the affinity fingerprint.
Furthermore, many unknown off-targets that have never been tested experimentally can exist for
a chemical, and they may play essential roles in modulating biological activity. Thus, it is not
trivial to handle many missing values in the observed bioassay data. Many computational
methods have been developed to predict genome-scale chemical-target binding profiles.
However, the issue of indirectly applying the observed or predicted target binding profile as the
feature to machine learning is its high dimensionality. It may hurt the performance of machine
learning, especially when the number of samples is small.

Thesis Layout
The central theme of this thesis is to address challenges in the machine learning of the bioactivity
modulated by novel chemicals. The thesis will be organized as follows:
In chapter 2 describe related and similar work: namely, recommender systems and pre-training
models. In chapter 3 propose to use a latent target interaction profile (LTIP) to represent the
chemical. The idea of LTIP is that the observed chemical activity profile can be embedded in a
low-dimensional vector of hidden (latent) variables that can be considered unobserved causal
factors. Expressly, statistical, computational methods used within QSAR models assume latent
unobserved variables, which account for overdispersion, which describes the observation that
variation is higher than expected. Some distributions do not have a parameter to fit the variability
of the observation or to implicitly model association structures. The hidden variables refer to
fundamental interactions which are not measured or are precisely hard to be measured.
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Unobserved hidden variables are predicted and estimated using the directly measured observed
variables. Predicted latent, hidden variables are used to interpret the observed variables better.

I have developed novel methods REMAP(1) and its variations that are based on a neighborhoodregularized weighted imputed one-class collaborative filtering (OCCF) algorithm to embed
chemicals and target spaces into low-rank models. In the benchmark studies, REMAP can
accurately reconstruct genome-scale chemical-target interactions. The top prediction from
REMAP has been experimentally validated. REMAP will predict the off-target interactions and
will be able to fill the missing drug-proteins data using the OCCF model that can scale to
significant off-target predictions. REMAP will complete missing edges in the large drug-protein
bipartite graph using already observed drug-protein data, drug-drug, and protein-protein
similarities graphs.

I will use the low-rank model of chemicals derived from REMAP to represent chemicals, i.e.,
LTIP. The neighborhood-regularized OCCF will predict missing edges in the drug-protein
bipartite algorithm. I used the resultant embedded low-dimensional vectors representing each
drug and protein, i.e., LTIP, as training features in machine learning algorithms. I conducted a
thorough and comprehensive evaluation process using seven cancer cell lines and six state-ofthe-art algorithms, namely, support vector machines (SVR), XGBoost (XGB), k-nearest
neighbors regressor (KNR), Random Forests (RF), and Extra trees regressor (EXTRA). Training
data instances were normalized and randomly separated into training, development, and testing
folds using Pearson's correlation coefficient between actual and predicted AUC of anti-cancer
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drugs as the performance metric. I compared low-features LTIP with several conventional high
dimensional molecular fingerprints and showed the performance improvement when using the
hidden representation, suggesting a better similarity measure than conventional fingerprints. I
further show the strength of the complementary feature of LTIP by showing a clear performance
improvement when combined with other fingerprints that are low correlated with LTIP. Using
cancer cell drug sensitivity as a benchmark, our results clearly show that LTIP outperforms
molecular fingerprints in many cases. Thus, LTIP provides a new tool for the predictive
modeling of chemical genomics. I also show the limitations when using LTIP and how its
performance can be further enhanced.

In Chapter 4, I have used Bidirectional Encoder Representations from Transformers (BERT) to
represent proteins. Specifically, I used BERT as an embedding model to extract molecule
features which can later be used in machine learning algorithms. The activation outputs of the
last layers of BERT encoder hidden layers can be directly used individually or combined using a
weighted layer scheme to train a supervised learning model. I used many unlabeled proteins from
the Pfam database in pre-training models, namely the masked token and subsequent sentence
predictions, to generate protein embeddings whose tokens are firmly connected and related.
Subsequently, I used the BERT models' features to predict missing drug-protein pairs and fill
missing affinities in the drug-protein matrix. Specifically, I used the CGKronRLS algorithm to
predict missing drug-protein edges. CGKronRLS uses the regularized least square technique to
minimize the loss function while applying a conjugate gradient algorithm to make orthogonal
steps on the loss function graph, resulting in linear steps arriving at the global minimum in much
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higher performance. I showed comparisons of CGKronRLS with other state-of-the-art
algorithms, namely, XGB and RF. In chapter 5, the conclusion and future work.

Chapter 2
Relevant Work
Recommender systems
The recommender system makes a prediction based on users' historical behaviors. Specifically, it
is to predict user preference for a set of items based on experience. In movies, music, and news
recommendation, the recommender system tries to capture the patterns that could help
recommend items to users based on historical user feedback. Users tend to like items like what
they liked before, and similar users will most likely like the same items. Similarly, chemical
compound molecules will likely bind to similar protein structures, and similar chemical
structures will most probably bind to the same protein target sites. Protein will represent items,
and drugs will represent users in the case of our studies. Drugs will be represented in the form of
fingerprint vectors which can be generated using the PaDEL-Descriptor. PaDEL-Descriptor is a
software developed using java language to create a quantitative representation for molecules
using its chemical features like atom type electro topological state descriptors, McGowan
volume, and molecular linear free energy relation descriptors. There are two recommender
systems: content-based and collaborative filtering or hybrid, that will use both types. The
content-based method requires many items' features rather than user interactions and feedback.
For example, specific detailed information about the cloth item will be needed instead of which
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clothes the user has bought previously. Collaborative filtering is a mechanism used to make
intelligent recommendations when missing edges in the adjacency matrix represent users and
items graph. The collaborative filtering will recommend items to users based on similarities
between users and items themselves. Specifically, it can recommend an item to user A based on
the interests of a similar user B. users and item embeddings can be learned without the need of
hand-engineering the features themselves. The learned embeddings will include rich information
about users and items that extensively describe a diverse range of initially not prominent
features. Embeddings vectors can be used as a robust similarity measure that can be used for best
recommendations. Concretely, embeddings vectors of items liked by similar users will be closer
in the embedding space, and embeddings vectors of users who like the same item will be closed
in the same embedding space. The recommender system can fill the "unknown" values in the
drugs—proteins matrix, which is highly sparse. The Nearest Neighborhood algorithm is the core
of One-Class Collaborative Filtering, OCCF. for example, given a drug in question, the similar
top drugs to the drug in question will be chosen, and the rule will be that the drug in question
will most likely bind to these top similar drugs proteins binding list. Formally, if I want to find
out the user, I, rating to a specific item, j, I take the average rating of the top similar X users with
the similarities used as a weight. Pearson or cosine similarities can be used to determine
similarities between any two users.
∑$#%& 𝑠𝑖𝑚(𝑢! , 𝑢# )𝑟#"
𝑟!" =
#𝑟𝑎𝑡𝑖𝑛𝑔𝑠(𝑥)
There are two main challenges with collaborative filtering, which are scalability and sparsity of
the adjacency matrix. Specifically, the number of features (items or proteins in our case)
becomes so huge that it could affect the accuracy and final predicted results. In the drug-protein
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problems, there are many proteins that we do not know their binding profiles with many drugs.
These missing binding profiles cannot be considered negative examples but mixed negative and
missing positive data.

The sparseness of positive data can also lead to the cold-start problem, which can be defined by
the difficulty of predicting the binding drug-protein affinity if the drug is new. There are many
missing values in the adjacency matrix; namely, we do not know the connecting edge between
each user and item or drug-protein pair in our case study. A dual regularized model using matrix
factorization could tackle the ambiguity problem using an integrated imputation, weighted
methods, and regularized similarities scores from both drugs and proteins. Specifically, the
unobserved proteins can be imputed to indicate the probability that the drug may bind to these
specific proteins. The weighting scheme will indicate how reliable is the imputed data. The
sparseness of known binding drug-proteins profiles will be tackled by including protein-protein
similarities and drug-drug scores matrices.

Matrix factorization comes in very handy when decomposing the adjacency matrix into two low
dimensionalities matrices that best describe the latent features of each item and user. Matrix
factorizations specify how each user is related and in line with a set of hidden, latent features and
how much each item is relevant to the same latent features. Two users may not pick the same
item, but they could be similar when comparing their latent features vector and hence the
possibility of sharing similar items set; this cannot be measured using a standard algorithm like
the nearest neighborhood. Formally, if we have the representing adjacency matrix, it can be
decomposed into representing the latent, hidden features matrices for users and items,
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respectively. Each user and item is represented as a vector of hidden features. Given the weight
matrix that will weigh individual edges between users and items, the non-negative matrix
factorization algorithm, NFM, will minimize the following loss function.

#

(

𝑚𝑖𝑛 2 2 𝑊 {𝑅 − (U . V ' )} + 𝜆(‖𝑈‖) + ‖𝑉‖) )
!

"

There is more than one way to optimize the non-convex function. The non-convex nature of
the problem does not allow to reach a global minimum due to the pairing between and, but
rather an approximated solution or specifically a local minimum. The alternative least square
algorithm can optimize the loss function by updating one of the low dimensional matrices
while fixing the other. Specifically, fixing and updating and fixing the just updated to update,
then repeating the same process until no more changes can be made according to a chosen
certain threshold.

Pre-training models
The advances in protein technologies have tremendously advanced in recent years, leading to the
highest growth in protein databases that need meaningful labels and annotations. These mostly
unlabeled protein databases contain a significant amount of biological data about their structure
and function that could be used in building efficient computational machine learning protein
models. The gap between labeled protein subsets and unlabeled proteins is exponentially
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growing. Bridging such a gap can significantly help to answer many of the biological questions,
especially evolution.
Linear chains of amino acids connected by covalent bonds are the basic building blocks of
proteins. Amino acids can be represented as alphabet characters, so a protein can be represented
as a discrete sequence of tokens X1, X2, where X is an alphabet. Sequence alignment can
significantly identify standard functions and evolution features when used with protein
sequences. The problem is that this method can be very computationally expensive, especially
when there are many proteins to consider. Also, some failures could be when two proteins share
a distant common ancestor in the evolution tree. Deep learning models can also be used, but they
will also be computationally expensive as they will need to be built from scratch, and
hyperparameters will need to be chosen, requiring a lot of training time. Pre-trained models can
be the solution for time-consuming learning models built from scratch. There are two types of
pre-trained models, fine-tuning and feature extraction. Training deep learning models using
stochastic gradient descent algorithms can be difficult and computationally expensive, especially
with massive, long protein sequences. The randomly initialized hyperparameters may cause the
algorithm to be slow to converge to an optimal value. Initializing the model with a prior
background which can later be regularized or fine-tuned, could be very efficient. For example,
suppose we have a model built for image classification. In that case, the hyperparameters matrix
can be extracted and used as initiation parameters for a new model with a different dataset for a
different classification task. The basic idea is that the first layers in deep learning models can be
very similar, and only the last layers need to be changed. Using a pre-trained model is like preadjusting the network's neurons to a particular state before the actual training for the supervised
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task. It is like shortening the searching range to optimize the neurons' hyperparameters and save
computational power and time.
The statistically learned hyperparameters will reflect the language's features and characteristics
and can be used with new sentences. An example for the fine-tuning models will be the
generative pre-trained transformers, openAI GPT. Pre-training models can also be used for
feature extraction as the hidden layers' matrices can represent images. These features can be used
as training features in different models e.g., image embeddings. An example of feature-based
models will be ELMO models. Following the similar idea of ELMO, OpenAI GPT expands the
unsupervised language model to a much larger scale by training on a giant collection of free text
corpora. Despite the similarity, GPT has two significant differences from ELMO. The model
architectures are different: ELMO uses a shallow concatenation of independently trained left-toright and right-to-left multi-layer LSTMs, while GPT is a multi-layer transformer decoder.
The use of contextualized embeddings in downstream tasks is different: ELMO feeds
embeddings into models customized for specific tasks as additional features, while GPT finetunes the same base model for all end tasks. The major disadvantage of both models is their
dependencies on unidirectional language models. Unidirectional models make predictions based
on the given token's left context or specifically previously seen words by the models, which will
hinder the unidirectional models' prediction ability. However, one would like to use both left and
proper contexts, giving rise to bidirectional models.
BERT, Bidirectional Encoder Representations from Transformers mitigates the unidirectional
disadvantage by using a masked language model. BERT employs two pre-training tasks, namely
the masked language model and next sentence prediction. It does that by randomly masks 15% of
the token positions at random for prediction. The transformer architecture is modified to include
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a classification layer right after the encoder's stack and a SoftMax layer to predict each masked
token or word's probability. The adapted transformer model is then forced to predict only the
masked words using the given sentence corps. The non-masked tokens are ignored during this
pre-training phase. As a result, BERT a more, but slowly converged, the context-aware model
will be built. The other model BERT uses during pre-training is the next sentence prediction,
NSP. The adapted transformer architecture will receive two sentences at the bottom of the
encoder stack. A token will separate the two sentences to differentiate them and be embedded
with positional encoding and time signals to account for the input sequences' order. The next
sentence model will predict If the second sentence follows the first sentence in the corps. 50 % of
the input sentences, the second sentence will be the second sentence in the input corps, while in
the other 50 %, the second sentence in the input pair will be chosen randomly from the corps.
These randomly chosen sentences are to create negative examples and avoid creating a bias
model. During the Fine-tuning phase, BERT will fine-tune and regularize all parameters in all
layers to adapt the model to each specific task. Compared to the slow pre-training phase, Finetuning is not computationally expensive. The transformer model is modified by adding a
SoftMax classification layer after the encoder stack to predict if the second sentence in the input
pair follows the first sentence in the input language corps. BERT can be used in many
applications. In question and answering models, SQuAD v1.1, BERT's input is a text of
sentences followed by a question. BERT will train a modified transformer model to learn two
different vectors that mark the answer's beginning and end. In name entity recognition, NER, the
input will be a sentence, and BERT will identify the entitles (date, person name….) within the
sentence. The vector representing each token word is the input for a SoftMax layer that will
generate a probability vector representing each label entitle possibility.
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BERT can be used as a feature extraction model where there will be no fine-tuning phase, and
only the pre-trained phase will be used. This computationally expensive matrix representing the
output of the hidden layers can be used directly as features representing input tokens in other
simple machine learning models for other tasks where transformers cannot be used. BERT model
size will play an essential factor in the final accuracy results. Increasing the number of hidden
layers can improve the results and increase the number of hyperparameters that need to be
regularized during pre-training and the fine-tuning phase by a significant scale. Also, increasing
the training instances and training steps will significantly improve results.

BERT's extraordinary success with different NLP tasks raises the question of the possibility of
applying BERT to biological sequences. Concretely defining the reasons for disturbing proteins'
ordinary functions can lead to better treatments and drug development. Sequence alignment
models can identify other proteins with similar structures, co-evolve with query proteins;
specifically, mutations will co-happen in similar proteins. Unfortunately, learning labeled data is
a high-cost effort. The most extensive corpus of unlabeled protein databases can be used in selfsupervised models. Specifically, one can apply BERT to protein sequences to encode biological
and internal structure relationships in the learned sequences. There is a gap between the
performance of self-supervised models and non-neural protein models due to the lack of a
unified, integrated evaluation paradigm. There is a need for a benchmarking suite to measure the
performance when applying BERT to biological problems. TAPE provides a set of five
biologically relevant semi-supervised learning tasks spread across different domains of protein
biology. TAPE will methodically measure the performance of learned embedded protein
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sequences during the BERT pre-training phase. TAPE focuses on three major biological areas,
namely, structure prediction, detection of remote homologs, and protein engineering. TAPE
splits data to make sure that models will generalize to unseen or short protein sequences. The
first tasks are the secondary structure prediction. Secondary protein structure is fundamental in
understanding the local geometry of the protein itself, which may answer many evolution
questions. SS prediction is a sequence-to-sequence prediction where the fine-tuning structure
prediction model will take the output of the pre-trained, with large unlabeled protein corpus,
BERT model to predict the structure of labeled protein sequences. The fine-tuned model can
later be used to predict unseen and unlabeled protein sequences. The second task, contact
prediction, will take paired data of two protein sequences, and the fine-tuning model will predict
if they are "in contact" or not. Precise protein contact information dramatically helps to
understand the 3D protein structures and their global function.
The third task is Remote Homology Detection (Evolutionary Understanding Task); the finetuning layer will classify the input sequence to different protein folds. Predicting remote
homologs can significantly help design antibody genes and detect distant similarities between
different input sequences that may not be detected using current similarities measures. The fourth
task, Fluorescence Landscape Prediction (Protein Engineering Task), is a regression task that
will map the input protein sequence into a value representing the log-fluorescence intensity of
the sequence. The regression model will distinguish between very similar input sequences and a
combination of unseen sequence mutations. The fifth task, Stability Landscape Prediction
(Protein Engineering Task), is a regression task that will map the input protein sequence to value
measuring the most extreme circumstances in which protein x maintains its fold above a
concentration threshold (a proxy for intrinsic stability). Designing stable proteins helps in
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developing safe and effective drugs. TAPE will provide a methodical framework that can
measure self-supervised model performance effectively, decreasing the gap between labeled and
unlabeled protein sequences. ESM inspected learning authentic biological properties through
training of very long sequence, 250M amino acids, protein sequence. 86 M proteins were used to
train different deep learning models, which helped to learn important biological characteristics at
different levels, including but not limited to evolutionary homology and information about the
secondary and tertiary structure. They showed that pre-train models, when followed by finetuning, outperform other models that do not apply pre-trained sequences in LSTM. They also
showed that extracted protein representations had information that is not included in the state-ofthe-art features. They further show that combining learned features through pre-training with
state-of-the-art features improves the results. They also show that dataset diversity significantly
improves final predicted results and the information included in the learned representations.

Chapter 3
Off-Target Identification Using Fast and Accurate Dual Regularized One-Class
Collaborative Filtering
A target-based drug is a drug that focuses on a specific genetic target itself with the intent of
chemically changing the specific disease gene or the gene product without changing any other
gene functions. The deadlock in drug discovery is to identify the drug list of affected targets
which defines its mode of action, MOA. The MOA of a drug can be described as the functional
and anatomic effects of a living organism due to exposure to the drug's chemical substance
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interactions. There is a big gap between MOA and the actual physiological responses of drugs.
This is mainly because each drug has off-target interactions. Unexpected off-target interactions
may disrupt other metabolic or signaling pathways resulting in unwanted side effects, sometimes
leading to loss of lives. Identifying gene signatures that mark the genetic activity for each drug is
crucial in developing stable and safe drugs. Adverse drug reactions can be a significant public
health problem and hinder safe drug development. On the other hand, adverse drug reactions can
be medicinal and curative.

Related Work
Many methods have been developed which link drugs to their phenotypes. Ye et al. in
try to close the gap between the drug's mechanism mode of Action, MOA, which is described
mainly by its biochemical interactions and the intended therapeutic efficacy. They used the side
effects as descriptors for the unintended off-target drugs' biochemical activities. They
hypothesized that if drugs have similar side effects, they may have some therapeutic effects
allowing potential drug repositioning. Ye et al.(2) has built a drug-drug network based on the
Jaccard index, using binary vectors representing the existence or no existence of side effects for
each drug, representing the similarities between drug-drug pairs. Side effects were represented as
vectors of zeroes and ones to represent the existence or no existence of each side effect. Jaccard
index cutoff was applied to build meaningful drug-drug correlations. Drug possible off-target
interactions can then be predicted using its neighborhood drugs within the network. Siorta et al.
has integrated the gene expressions of diseases and cancer cell lines treated with drugs to predict
a possible drug repurposing. Diseases' Gene expressions were extracted by comparing infected
cell lines to standard cell lines and extracting genes that are up or down-regulated in both cases.
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Comparing the disease gene expressions to the drug-treated cell lines and extracting the set of
reversed genes may indicate a possible unknown therapeutic indication. Siorta et al.(3) central
hypothesis is that the negative similarities between the disease and drug-treated cancer lines will
measure reversed genes and identify the negative relationship between the two gene expressions.
Wang et.(4) introduce an algorithm that will use a kernel to integrate several heterogeneous data
sources to infer possible drug-disease relationships. Specifically, they use the kernel to integrate
the drug similarities extracted from chemical structures, target proteins, side effects, disease
similarities extracted from disease semantic phenotypes. The resultant integrated vectors can be
used as instance features to build SVM models to predict drug-disease relationships. Gottlieb et
al.(5) hypothesize that similar drugs will treat similar diseases. They integrate several drug-drug
and disease-disease similarity measures to create a vector of scores that can be used as
classification features in prediction models. Each score (feature) is constructed using one drugdrug and disease-disease similarity measure. Each instance in the training set will represent an
already known drug-disease association. Then a logistic regression model will predict the
probability that a query drug-disease is associated.
On the other hand, gene expression can be considered a good bioactivity indication for drugs and
diseases. The choice of the gene subsets that accurately represent the gene expression could be a
problem. Iorio et al.(6) tried to overcome such a problem by computing synthetic gene
expressions that collectively summarize different gene expressions across different cell lines
treated with the same drug with different dosages. The connectivity map contains 6100 gene
expressions obtained for five different cells with different dosages of 1309 molecules. Iorio et al.
merged the five expressions for different cells to get one "consensus" signature for each drug.
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Then a drug network was built using the distance as the similarity measure between and drug
pair.
Iwata et al. (7) build a model by defining a descriptor for each drug-disease association using
side effects and diseases ( disease-causing genes and diagnostic markers) features. Specifically,
each instance in the training model will consist of the tensor product of side effects features and
disease features. The problem is formulated as a classification problem, with each instance
representing the existence of a drug-disease association.
Linear logistic regression with L2-regularization was used to predict unknown drug-disease
associations. Most of these methods relied on measuring the similarities between drugs and their
corresponding side effects and the diseases they were developed for. These methods' central
hypothesis is that similar drugs will probably share the same target lists, allowing for a possible
drug repurposing. Also, similar side effects will probably share similar therapeutic effects.
Besides, measuring the reverse up and down-regulated between drugs and diseases gene
expression could play an essential role in drug repurposing and predicting possible drug-drug
interactions when more than one drug is co-administered. The central hypothesis is that an up (or
down) regulated in a disease gene expression with the reverse state of the same gene in the druggene expression could trigger a possible therapeutic effect. The resulting scores of docking drug
molecules to protein binding sites were also used as features to prediction algorithms. Despite
their successes, all these methods share several common limitations:
1. Only observed data, which are highly biased and incomplete, are considered in the
modeling.
2. These methods can only be applied to existing drugs that have observed biological or
clinical activities.
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3. These methods are computationally expensive, mainly when applied to the full genomewide spectrum.
Thus, these methods are incapable of predicting the bioactivity of novel chemicals.

Distinguishing the genome-wide off-targets for drug compounds is crucial in the drug discovery
process, paving the way for designing safe, efficient, less costly, and multipurpose drug
compounds. When using QSAR models to predict drug-protein interaction binding information,
the fundamental rule is that chemically structured similar drugs will bind to similarly structured
proteins. Thus, any new machine learning models must rely on both similarities data from drugs
and protein structure. Several sophisticated computational methods have been introduced to
associate the chemical and genomic spectrum with identifying possible off-target interactions.
Techniques like Gaussian Interaction Profile (GIP)(8), Weighted Nearest Neighbor (WNN)(9),
Regularized Least Squares (RLS) classifier showed success in their drug-proteins prediction
results. Neighborhood Regularized LogisticMatrix Factorization (NRLMF)(10) and Kernelized
Bayesian Matrix Factorization (KBMF)(11) are two of the most successful methods.

Despite their success, these algorithms had some disadvantages that restrained their applicability
to the genome-wide off-target prediction models. Firstly, their high memory and CPU
consumption, in addition to the lengthy running time, requires infrastructure that is not available
all the time. Secondly, the lack of representative negative examples (i.e., chemical-protein pairs
that are not associated) biases the predictions and lowers the accuracy of the algorithms. There
are many open and public databases that can be used as bioinformatics and chemoinformatic
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resources. Although these databases, ZINC, ChEMBL, DrugBank, PubChem, and UniProt, have
provided large-scale drug-target interaction binding data, the available known associations are
sparse and few. In addition to that, the known negative examples are very few and hinder the
application of many statistical machine learning models to generate a whole known genomewide association. Randomly sampling negative examples or considering missing data as negative
examples will bias the model and generate nonviable results. Also, the algorithms were applied
to the same gene family using a few drugs and proteins, and when considering the genome-wide
spectrum, their results are ambiguous.

Collaboration Filtering and REMAP
Collaboration Filtering systems seek to predict users' preferences for items based on the history
of the rest of users' preferences. Collaboration Filtering algorithms with only one positive class
are referred to as one-class collaboration algorithm, OCCF, the core of recommender systems.
Recommender systems aim to design a mathematical function that predicts the "scoring" or
"probability" that a drug will "prefer" or "be associated" with a protein. The models will mainly
depend on known drug-protein associations to predict missing ones. The concept is simple:
similar drugs will probably bind or be associated with similar targets. A collaborative filtering
system can be of two types a binary or non-binary. In a binary case, items are either positive or
negative, like clicking on a web link or not clicking. In the non-binary case, the item is rated
based on a score like in movie ratings. There will always be a lot of data missing. The one-class
problem can suffer from the imbalance problem where one class is highly represented within the
dataset. The other class has very few instances; sampling negative examples can resolve the
problem. Unknown binding information can be either considered as unknown or negative while
training the model. Considering all missing data as unknown and ignoring these instances is a
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waste of information sources and will lead to bias results ( the model will always predict new
instances as positive). Considering all missing as negative examples will lead to an imbalance
class problem, computationally expensive, and the loss of identifying hidden unobserved positive
examples that were wrongly considered negatives. There is a need for a method that balances all
missing as negative algorithms and all missing as unknown methods while using the contained
information in the missing unobserved data. Imputing the unobserved missing data will indicate
the probability of a possible drug-protein association. Weighting the imputed data will indicate
how reliable is the binding probability. The sparseness of binding data (positive examples) is
tackled by encoding both drugs and proteins' side information as two graph regularization terms.
REMAP is built around Collaborative filtering, which is the core of recommender systems. Users
tend to like items that are like what they liked before, and similar users will most likely like the
same items.
Similarly, chemical compound molecules will likely bind to similar protein structures, and
similar chemical structures will most probably bind to the same protein target sites. REMAP is
one-class Collaborative filtering that will utilize the historical feedback data of the target binding
activities. Thus, negative data are not needed but can be used. REMAP will utilize a dualregularized OCCF system that integrates two state-of-the-art systems, namely weighting and
imputation. Indeed, this will have two advantages. First, it will impute unassociated data as the
drugs may bind to unseen biological targets, and second, it will weigh the imputed data to
indicate its reliability. Typically, the imputed unassociated data will represent how likely the
compound chemical will bind to the protein target site, and the weight will indicate how reliable
is the binding probability. REMAP will have three matrices, R, T, and C, representing the
chemical-protein, proteins-proteins, and chemical-chemical associations. Assuming that the
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chemical-proteins adjacency matrix can be reconstructed from the dot product of the latent lowdimensional embedding proteins and chemical matrices, one can obtain the probability that a
drug will likely bind to an unknown target.

Biological networks, including pathways, genes, drug-side effects database, etc., can be viewed
as graphs. Furthermore, chemical molecules can be viewed as labeled graphs where atoms
represent the vertices, and the bonds represent the edges. The classification of these graphs plays
a crucial part in determining their effectiveness and toxicity during the drug discovery process.
No doubt, modeling biological interactions using graph analytics, including but not limited to
node classification and link prediction, can bring more insights into how to make efficient use of
the extracted hidden graph information. Despite the need for graph analytics, it suffers from the
high computational and space cost requirements due to the high dimensional feature vectors used
in the machine learning models. Graph embedding techniques can solve the problem by
embedding the high dimensional feature vectors into a low dimensional coordinate system while
preserving important graph features like structure and connectivity. Graph embedding algorithms
output can be input as features into computational models that can significantly help major hot
current applications like drug repurposing and predicting adverse drugs' side effects. Graph
embedding output vectors will face several challenges that will need to be addressed. The
resultant embedded vectors will have implicitly inherent nodes' properties, namely features and
connectivity. Specifically, each vector will have to preserve the graph structure and node
attributes, mainly depending on the application. The embedding algorithm will have to be
scalable to model nowadays network, which may span millions of nodes while optimizing the
embedded output vectors' dimensionality. The higher the dimensions, the more information it
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will include, but the higher the computational and space cost, while lower dimensions may help
in some application link prediction if the vectors embedding algorithm emphasizes the
connectivity information.
A total of 3500 proteins (the value) were tested for associations with chemical compounds from
different public databases like ZINC, ChEMBL, and Drug-Bank.
Since the number of negatives is unknown, another measure needed to be formulated. REMAP
was evaluated using the top 1% ranked scores for each chemical. in other words, the cutoffs that
were used were the top 35th ranked scores for each chemical row in . The true positive rate that
was used to measure REMAP is given by

∑ 𝒕𝒓𝒖𝒆 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆𝒔
∑ 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆𝒔
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Similarities comparisons
𝑳𝒂𝒓𝒈𝒆 𝒄𝒐𝒍𝒍𝒆𝒄𝒕𝒊𝒐𝒏 𝒐𝒇
𝒑𝒓𝒐𝒕𝒊𝒆𝒏
And drug binding
and interactions
databases

Chemical – chemical
similarities matrix
𝓒(𝒎 , 𝒎)

Protein – Protein
similarities matrix
𝚻(𝒏 , 𝒏)

Drug – Protein
associations matrix
𝓡(𝒎 , 𝒏)
The U matrix
will be used as
features in
prediction
QSAR models

Machine learning
statistical models
for QSAR

𝑼(𝒎 , 𝒓)
matrix
low-rank
hidden
features
of
chemicals

𝑽(𝒏, 𝒓)
matrix
low-rank
hidden
features of
proteins

Figure 3.1 The REMAP Algorithm
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Low-matrix
factorization
updates (REMAP
algorithm)

REMAP Parameters
Symbol
Description and definition
The
binding
activities
adjacency
matrix between chemicals and proteins
𝑹
The chemical-chemical and protein-protein similarities matrices
𝑪, 𝑻
𝑪(𝒄𝟏 ,𝒄𝟐 ) The similarity score between chemical 𝒄& and 𝒄) .
𝑷(𝒑𝟏 ,𝒑𝟐 ) The similarity score between proteins 𝑝& and 𝑝)
𝑫𝑪 , 𝑫𝑻 The degree of matrices 𝐶, 𝑇 repspectivley
𝑼, 𝑽
The chemical-side and protein-side low-rank matrix factorization of 𝑅
𝑹(𝒊,𝒋)
The association value between the 𝑖 34 chemical and the 𝑗34 protein.
𝑹(𝒊,:)
The 𝑖 34 row of the 𝑅 matrix
𝑹(:,𝒋)
The 𝑗34 row of the 𝑅 matrix
The transpose of matrix 𝑅
𝑹𝑻
𝒕𝒓(𝑹)
The trace of matrix 𝑅
The penalty weight on observed and unobserved binding activity associations
𝑷𝒘𝒕
between chemicals and proteins which indicate the reliability of assigned probability
of true positive association
𝑷𝒊𝒎𝒑
𝑷𝒓𝒆𝒈
𝑷𝒄𝒉𝒆𝒎
𝑷𝒑𝒓𝒐𝒕
𝒓
𝑷𝒊𝒕𝒆𝒓
ℙ(𝒊,𝒋)

The imputed value that indicates the probability that the unobserved association is a
true positive indication of a real binding activity
The regularization parameter which is used to prevent overfitting
The importance parameter for chemical-chemical similarity
The importance parameter for protein-protein similarity
The length of the compressed features’ space.
The number of iterations while minimizing the objective function
The row prediction score of the 𝑖 34 chemical and the 𝑗34 protein
Table 3.1 REMAP Hyperparameters

Formally, I will use the neighborhood-regularized weighted imputed one-class collaborative
filtering algorithm(28). Given n chemicals and m proteins, the algorithm's inputs are the three
matrices, R, T and C ,which represent observed chemical-protein interactions, protein-protein
similarities, and chemical-chemical similarities, respectively. 𝑅(𝑖, 𝑗) = 1 if the 𝑖 34 chemical is
associated with the 𝑗34 protein and 𝑅(𝑖, 𝑗) = 0 otherwise. The 𝐶# × # will hold the similarity
scores between chemicals such that 0 < 𝐶(𝑖, 𝑗) < 1 will represent the Tanimoto coefficientbased similarity score between the 𝑖 34 chemical and the 𝑗34 chemical. The protein matrix
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𝑇( ×( will be in the same format where 0 < 𝑇(𝑖, 𝑗) < 1 represents the protein sequence
similarity.

It will be assumed that a small number of features can capture most of the characteristics
between drug molecules and proteins. Expressly, I will assume that R can be approximately
reconstructed from two low-rank matrices, 𝑈 (chemical side) and 𝑉 (protein side), according to
the following:
#

(

2 2{𝑅 − (U . V ' )} − −(1)
!

"

The algorithm optimizes the loss function in Equation (1) to learn low-dimensional
representations (i.e., low-rank features) of chemicals and proteins, 𝑈 and 𝑉, respectively.

𝐽(𝑅, 𝑈𝑉) = min 2 𝑃B3 (𝑖, 𝑗) ⨀f𝑅(𝑖, 𝑗) + 𝑃!(C (𝑖, 𝑗) − 𝑈(!,:) . 𝑉 ' (",:)g
!,"@A

)

(!,")

+ 𝑝DEF (‖𝑈‖) + ‖𝑉‖) ) + 𝑝G4E( 𝑡𝑟(𝑈 ' (𝐷G − 𝐶)𝑈)
+ 𝑝CDH3 𝑡𝑟(𝑉 ' (𝐷' − 𝑇)𝑉)

𝑆. 𝑇 𝑈, 𝑉 > 0 − −(2)

Where 𝑃B3 (𝑖, 𝑗) is the penalty of the loss. 𝑃B3 (𝑖, 𝑗) = 1.0 whenever 𝑅!," = 1 and otherwise
𝑃B3 (𝑖, 𝑗) ∈ [0,1]. 𝑃!(C (𝑖, 𝑗) is the imputation of the unobserved association between chemical 𝑖
and protein 𝑗. 𝑃!(C (𝑖, 𝑗) = 0 whenever 𝑅!," = 1 and otherwise 𝑃!(C (𝑖, 𝑗) ∈ [0,1]. 𝑝DEF is the
regularization parameter to control the regularization term (||𝑈||)I + ||𝑉||)J ) which is used to
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prevent overfitting. 𝐷G and 𝐷' is the degree matrix of C and T, respectively. The last two terms
will force similar chemicals and proteins to have similar low-rank features.

The optimization function represented by Eq 1 can be formulated as a non-negative matrix
decomposition problem, NMF. The basic idea of NMF is to decompose a non-negative
matrix, 𝑅# × ( into another two smaller non-negative matrices , 𝑈# × D & 𝑉D × ( , which are also
strictly positive element wise. The Gradient descent algorithm can be used to optimize the cost
function 𝐽. 𝑈 and 𝑉 are not jointly convex in Eq 1 , so I will need to alternatively update one
while fixing the other when applying the gradient descent algorithm. The gradient of the cost
function will be a vector pointing to the maximum direction so the reverse vector ( the negative
of the gradient vector) will point towards the minimum which allows us to formulate the
following update rules, Eq2&3, for the gradient descent algorithm. Where ∇I & ∇J are the
partial derivatives of 𝐽(𝑅, 𝑈𝑉) with respect to 𝑈 and 𝑉. 𝜇 will be the learning rate that will
control the step taken on the cost function graph towards the minimum. The learning rate is an
algorithm parameter that can be tuned and can affect how quickly I can find the minimum. It can
also be adjusted to ensure the strictly positive constraints of the optimization function in hand. If
I can remove the subtracting terms from our resultant update rules, all resultant factorized
matrices elements will be strictly positive. Choosing the learning rate in Eq3 will ensure that and
convert the additive update rules in Eq2&3 into the multiplicative form which will impose the
positivity constraints on all predicted 𝑈𝑉.

Looking at the partial derivative Equation 1 with respect to 𝑈 in more details and ignoring all
terms that are related 𝑉 as they will be constants, I can derive the following :
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)

𝐽 = 𝑃B3 (𝑖, 𝑗) ⨀f𝑅(𝑖, 𝑗) + 𝑃!(C (𝑖, 𝑗) − 𝑈(!,:) . 𝑉 ' (",:) g + 𝑝DEF ‖𝑈‖)
+ 𝑝G4E( 𝑡𝑟(𝑈 ' (𝐷G − 𝐶)𝑈)

Let A = 𝑃B3 ⨀f𝑅 + 𝑃!(C g , B = 𝑃B3 ⨀(U . V ' ) , M = (A − B)
𝑓=𝑀∶𝑀
Where ( : ) is the Frobenius inner product. Then taking the derivative will give us :
𝑑𝑓 = 2𝑀 ∶ 𝑑𝑀 = 2𝑀 ∶ (𝑑𝐴 − 𝑑𝐵)
But for any matrices x , y and z we have the following rules :

𝑥: (𝑦 − 𝑧) = (𝑥: 𝑦) − (𝑥 ∶ 𝑧) − −(𝑎)
𝑑(𝑥 ⨀ 𝑦) = (𝑑𝑥)⨀𝑦 + 𝑥⨀(𝑑𝑌) − −(𝑏)
𝑥 ∶ 𝑦 ⨀ 𝑧 = 𝑥 ⨀ 𝑦 ∶ 𝑧 − −(𝑐)
𝑥 ∶ 𝑦 . 𝑧 = (𝑦 ' . 𝑥 ) ∶ 𝑧 = (𝑥 . 𝑧 ' ): 𝑦 (𝑑)
K ‖I ‖#
KI

= 2𝑈 − − − (𝑒) ----

𝛿𝑡𝑟(𝑈 ' (𝐷G − 𝐶)𝑈)
= (𝐷G − 𝐶)' 𝑈 + (𝐷G − 𝐶)𝑈 − − − (𝑓)
𝛿𝑈
𝑡ℎ𝑒𝑛 𝑤𝑒 𝑐𝑎𝑛 𝑤𝑟𝑖𝑡𝑒 ∶
𝑑𝑓 = (2𝑀 ∶ 𝑑𝐴) − (2𝑀: 𝑑𝐵), 𝑡𝑎𝑘𝑖𝑛𝑔 𝑑𝑒𝑟𝑣𝑖𝑎𝑡𝑖𝑣𝑒 𝑤. 𝑟. 𝑡 𝑈 𝑎𝑛𝑑 𝑢𝑠𝑖𝑛𝑔 𝑟𝑢𝑙𝑒 (𝑎) (b)
𝑑𝑓 = − 2𝑀 ∶ 𝑃B3 ⨀ 𝑑(U . V ' ) , 𝑢𝑠𝑖𝑛𝑔 𝑟𝑢𝑙𝑒 (𝑏), (𝑐)
𝑑𝑓 = − 2𝑃B3 ⨀𝑀 ∶ (𝑑𝑈𝑉 ' + 𝑈𝑑𝑉 ' ), 𝑢𝑠𝑖𝑛𝑔 𝑟𝑢𝑙𝑒 (𝑎)𝑎𝑛𝑑 𝑠𝑒𝑡𝑡𝑖𝑛𝑔 𝑑𝑉 ' = 0
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𝑑𝑓 = − 2𝑃B3 ⨀𝑀 ∶ 𝑑𝑈𝑉 ' = 2𝑃B3 ⨀𝑀𝑉 ∶ 𝑑𝑈 , 𝑢𝑠𝑖𝑛𝑔 𝑟𝑢𝑙𝑒 (𝑑) [ 𝑠𝑒𝑡𝑡𝑖𝑛𝑔 𝑥 = 2𝑃B3 ⨀𝑀 , 𝑧 =
𝑉 ' , 𝑦 = 𝑑𝑈]

𝑑𝑓 = −2𝑃B3 ⨀ ˆ𝑃B3 ⨀f𝑅 + 𝑃!(C g − 𝑃B3 ⨀(U . V ' )‰ 𝑉 ∶ 𝑑𝑈

MN
MI

MN
MI

= − 2𝑃B3 ⨀ ˆ𝑃B3 ⨀f𝑅 + 𝑃!(C g − 𝑃B3 ⨀(U . V ' )‰ 𝑉

= − 2𝑃B3 ⨀ 𝑃B3 ⨀ ˆf𝑅 + 𝑃!(C g‰ . 𝑉 + 2𝑃B3 ⨀ 𝑃B3 ⨀ (U . V ' ). 𝑉

𝑈 = 𝑈 − 𝜇I ⨀ ∇I 𝐽(𝑅, 𝑈𝑉) --- (2)
𝑉 = 𝑉 − 𝜇J ⨀ ∇J 𝐽(𝑅, 𝑈𝑉) --- (3)
Where 𝜇I and 𝜇J are the leaning rate and ∇I and ∇J are the gradient of the cost function with
respect to 𝑈 , 𝑉 respectively.

𝜇I =

2Šf 𝑃B3 ⨀ 𝑃B3

𝑈
− −(4)
⨀( 𝑈𝑉 ' )g𝑉 + 𝑃G4E( 𝐷G 𝑈 + 𝑃DEF 𝑈‹

𝐷G , 𝐶 𝑎𝑟𝑒 𝑏𝑜𝑡ℎ 𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑖𝑐 𝑚𝑎𝑡𝑟𝑖𝑐𝑒𝑠 𝑎𝑛𝑑 𝑢𝑠𝑖𝑛𝑔 𝑟𝑢𝑙𝑒 (𝑓) 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑑𝑒𝑟𝑖𝑣𝑎𝑡𝑖𝑣𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑡𝑟𝑎𝑐𝑒 , 𝑤𝑒 𝑓𝑖𝑛𝑎𝑙𝑙𝑦 𝑔𝑒𝑡
∶

& OP
) OI

= −( 𝑃B3 ⨀ 𝑃B3 ⨀ ( 𝑅 + 𝑃)) 𝑉 + ( 𝑃B3 ⨀ 𝑃B3 ⨀ ( 𝑈𝑉 ' ))𝑉 + 𝑃DEF 𝑈 + 𝑃G4E( 𝐷G 𝑈 −

𝑃G4E( 𝐶𝑈

--- (5)

Substituting into Eq 2,3 using Eq 4,5 get the following :
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𝑈(!,D) ← 𝑈(!,D)

Šf 𝑃B3 ⨀ 𝑃B3 ⨀( 𝑅 + 𝑃)g𝑉 + 𝑃G4E( 𝐶𝑈‹(!,D)
Šf 𝑃B3 ⨀ 𝑃B3 ⨀( 𝑈𝑉 ' )g𝑉 + 𝑃G4E( 𝐷G 𝑈 + 𝑃DEF 𝑈‹(!,D)

− −(6)

I can further make the step smaller

Šf 𝑃B3 ⨀ 𝑃B3 ⨀( 𝑅 + 𝑃)g𝑉 + 𝑃G4E( 𝐶𝑈‹(!,D)

𝑈(!,D) ← 𝑈(!,D) •
− −(5)
Šf 𝑃B3 ⨀ 𝑃B3 ⨀( 𝑈𝑉 ' )g𝑉 + 𝑃G4E( 𝐷G 𝑈 + 𝑃DEF 𝑈 ‹(!,D)

Eq 5 introduces a dense (𝑅 + 𝑃)# × ( matrix and a 𝑃B3 which is another 𝑛 × 𝑚 matrix which
could be very computationally expensive in terms of space and CPU time. I can further simplify
the equation as follows:

𝑈 𝑉'
ℙ(!,D) = “ (!,:) (",:)
0

𝑖𝑓 (𝑖, 𝑗) 𝑖𝑠 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒

Α& (!,D)
𝑈(!,D) ← 𝑈(!,D) ”
Β& (!,D)

Where ,
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Α& = ( 1 − 𝑤𝑝)𝑅𝑉 + 𝑤𝑝 1# × & ( 1& × ( 𝑉) + 𝑃G4E( 𝐶𝑈

B& = ( 1 − 𝑤𝑝)ℙ𝑉 + 𝑤𝑈(𝑉 ' 𝑉) + 𝑃DEF 𝑈 + 𝑃G4E( 𝐷G 𝑈

Using the low-rank features of chemicals 𝑈,and 𝑉 the complete protein-chemical interaction
matrix can be reconstructed. Thus, 𝑈 and 𝑉 can be considered as hidden variables, i.e., latent
vectors representations, which determine both observed and unobserved chemical binding
profiles across all proteins. Specifically , the 𝑖 34 row in 𝑈 can be considered as the predicted
behavior of the 𝑖 34 drug in the genome-wide protein spectrum and the dug-dug similarity space
but shrank into 𝑟 length. Similarly, the 𝑖 34 column in the 𝑉 matrix can be considered the
predicted behavior of the 𝑖 34 drug in the genome-wide protein spectrum and protein-protein
Similarly space but shrunk into 𝑟 length. Notably, it can be assumed that all chemicals in our
benchmark data set are novel, i.e., I do not know their molecular targets.

The fingerprint that was used is the Extended Connectivity Fingerprint (ECFP) to represent
drugs. To determine if two drugs 𝑐& and 𝑐) , the Tanimoto dissimilarity coefficient 𝑑3Q(!(G$ ,G# )
was used to calculate the similarity score.

𝐶(G$ ,G# ) = 1 − 𝑑3Q(!(G$ ,G# )
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The raw predicted score for the 𝑖 34 chemical to bind the 𝑗34 protein can be calculated by 𝑃(!,") =
𝑈(!,:) . 𝑉 ' (",:) . The raw scores were adjusted based on the ratio of observed positive and negative
cases when the negative data are available (explained in the prediction score adjustment section).
Chemical similarity scores below 0.5 were treated as noise and set to 0.

Protein-protein similarity scores are also one of the required inputs for REMAP. The similarity
between two proteins was calculated based on their sequence similarity using NCBI BLAST
with an e-value threshold of 1 × 10R)A and its default options. The unknown missing binding
dug-protein data within the genome-wide spectrum present a challenge when testing the
performance of REMAP. The Receiver Operating Characteristic (ROC) curve can be used to
measure the robustness of the machine learning REMAP model but with some changes so that it
does not seem dependent on true negatives, which may be hidden in the missing untested drugprotein associations. So, Within the top 1 % predicted scores for each drug, one can calculate the
number of actual TRUE positives within the top 35 scores and divide that by conditions positives
( 35 scores). formally the true positive rate, TPR, can be measured using :

∑ 𝒕𝒓𝒖𝒆 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆𝒔
∑ 𝒄𝒐𝒏𝒅𝒊𝒕𝒊𝒐𝒏 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆𝒔
Examining existing approved drugs for other possible treatments is one of the leading research
goals in the pharmaceutical industry. The low rank factorized matrix 𝑈 can be used as the
interaction profiles for drugs but within a compressed representation space. Measuring the
similarities between drug rows within the 𝑈 matrix can provide valuable information about each
drug's possible treatments. The cosine similarity was used to discover unknown possible usages
for drugs :
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››››››⃗
››››››⃗
𝑈G$ . 𝑈
G#

𝐶𝑜𝑠𝑖𝑛𝑒 𝑠𝑖𝑚𝑖𝑙𝑖𝑎𝑟𝑡𝑦 =

•ž𝑈𝒄𝟏 ž

. •ž𝑈𝒄# ž

Chapter 4
Biological Representation of Chemicals Using Latent Target Interaction Profile
The fundamental idea of the LTIP method is to represent chemicals in their biological context, in
this case, as the low-dimensional representation (i.e., latent factor) of their global target binding
profile. When representing the chemical-protein interactions as a bipartite graph where chemicals
and proteins are nodes and their interactions are edges, the LTIP is the graph's chemical node
embedding. There are three steps, as shown in Fig. 1.
Step 1. Given a set of chemicals of interest, the set is incorporated into a high-confident
chemical-protein interaction matrix derived from ChEMBL (12) and DrugBank (13), which
includes around 200,000 chemicals and 3,500 proteins.
Step 2. Given the known protein-chemical interaction matrix from step 1, REMAP algorithm is
applied to derive the LTIPs of chemicals of interest.
Step 3. The LTIPs derived in Step 2 are used as features to train machine learning models.
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Figure 4.1. Schema of chemical fingerprint, affinity fingerprint, and proposed LTIP for predictive
modeling of bioactivity.
Blue arrow represents observed chemical-protein interactions and protein-bioactivity
associations. “1” and “?” denote observed and unknown interactions (i.e., missing data) in the
interaction matrix, respectively.

Performance evaluation
The main goal here (14) is to evaluate whether LTIP has better predictive power than standard
chemical fingerprints. I did not compare LTIP with the experimentally determined affinity
fingerprint because they are not available for the chemicals in most cases, especially for novel
chemicals, including our benchmark. In other words, affinity fingerprints are often not applicable
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in practice. I compared LTIP with standard fingerprints, including Atom Pairs 2D (ap2d), Atom
Pairs 2D count (ap2dc), Extended, Estate (esfp), Klekota-Roth (krfp), Klekota-Roth Count (krc),
MACCS, Pubchem (pcfp), and Substructure (ssfp). In this study, cancer cell line drug sensitivity
was used as a benchmark . To ensure a comprehensive evaluation, a total of 7 different cancer
cell lines were used across all fingerprints used for comparisons and LTIP as well. 6 state-of-theart algorithms were used to build the machine learning models to assess the predictive power for
standard fingerprints and LTIP. Mainly, I used support vector machines (SVR), XGBoost
(XGB), k-nearest neighbors regressor (KNR), Random Forests (RF), and Extra trees regressor
(EXTR).
A Necessary normalization procedure was applied to training and testing folds whenever it was
needed. Although the deep neural network has become the most popular method in machine
learning, it may not be suitable for our data set since the number of features is usually more than
1000, but the number of samples is only 124. A regression model was built using the fingerprint
or LTIP of each chemical as the feature. The target variable is the area under of drug response
curve (AUC) for each chemical against each
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SVR Hyperparameters name
Kernel

Hyperparameters description
Type of Kernels used

C

The penalty parameter of the
error term
The coefficient used with
kernels ,’rbf’,’sigmoid’
and ‘poly’
Only used as independent term
with kernels ‘poly’ and
‘sigmoid’
The polynomial
kernel,’poly’, function
degree
The distance between the
predicted and actual value
within which no penalty is
associated with the training
loss

gamma

coef0

degree

epsilon

Table 4.1 SVR hyperparameters
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Value
{ 'linear',
'rbf','poly','sigmoid'}
{ 0.5,1,10,30}
{'auto',0.0001, 0.0005,
0.001, 0.005, 0.01, 0.1}
{0.00,0.03,0.05}

{3,5,7}

{0.1,0.2,0.3}

EXTR Hyperparameters
name
min_impurity_split
XGB Hyperparameters
name
reg_alpha

min_samples_split
reg_lambda

min_samples_leaf
max_depth

n_estimators
n_estimators
max_features
objective

Hyperparameters
Value
description
The
threshold abovedescription
which
{1e-7,1e-6,1e-5,1e18}
Hyperparameters
Value
split will happen while
growing the tree. It is also
called
early stopping
L1 regularization
term that will
{0,0.1,0.2,0.3}
threshold.
This
is
to
prevent
control weights. The higher the
overfitting.
value the mode conservative the
The
minimum number of
{2,5,7,18}
model
samples
required term
at an that will
L2 regularization
{0,0.1,0.2,0.3}
internal
node
for
a
split
to
control weights. The higher the
happen.
is toconservative
prevent
value theThis
mode
the
overfitting.
model
The
The minimum
maximumnumber
depth ofofthe {1,3,5,7,18}
{4}
samples
that
must
exist
at
model’s-built tree. The deeper
each
leaf.the more likely the
the tree,
The
number
of trees
inoverfitting
the
{1000}
model
will suffer
from
forest.
The number of boosted trees
{50,100,200,1000}
The
of features
{10,20,30,40,50,60,70,80,90}
thatnumber
will be built
and fit. to
consider
whentask
looking
The learning
of thefor
{'reg:linear'}
the
best
split
XGBRegressor() object instance.
'reg:linear' means linear
regression

learning_rate

It is used to control overfitting. It
makes the boosting more
conservative by reducing the
features’ importance.

Table 4.2 EXTR hyperparameters
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{0.1,0.2,0.3,0.4}

KNR Hyperparameters
EXTR
HyperparametersnameHyperparameters
Hyperparameters description
ValueValue
name
description
weights
The neighbor’s function that
{'uniform','distance'}
min_impurity_split
The
threshold
above
which
{1e-7,1e-6,1e-5,1e18}
are
being used.
‘uniform’
split
willan
happen
while for each
uses
equal weight
growing
neighbor.
the tree.
’distance’
It is also will use
called
the inverse
early stopping
of the distance so a
threshold.
This is towill
prevent
closer neighbor
have a
overfitting.
higher weight and a further
neighbor
willnumber
have a of
lower {2,5,7,18}
min_samples_split
The
minimum
weight.required at an
samples
internal
node for
split to
n_neighbors
The number
ofanearest
{3,5,18}
happen.
neighbors
This that
is to will
prevent
be used to
overfitting.
find the final prediction.
min_samples_leaf
algorithm
The
The
minimum
algorithm
number
used to
of find the
{1,3,5,7,18}
{‘auto’}
samples
must exist
at
nearestthat
neighbor.
‘auto’
will
each
try leaf.
to find the best algorithm to
find
the nearest
neighbor
n_estimators
The
number
of trees
in the
{1000}
based on the samples passed
forest.
when
fitting
model.
max_features
The
number
of the
features
to
{10,20,30,40,50,60,70,80,90}
available
algorithms
consider when looking for
kd_tree’
theare,’ball_tree’,
best split
and ‘brute’
n_jobs
The number of parallel jobs
{18}
while searching for the nearest
neighbor.

Table 4.3 KNR hyperparameters
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RF Hyperparameters name Hyperparameters
description
min_impurity_split
The threshold above which
split will happen while
growing the tree. It is also
called early stopping
threshold. This is to prevent
overfitting.
min_samples_split
The minimum number of
samples required at an
internal node for a split to
happen. This is to prevent
overfitting.
min_samples_leaf
The minimum number of
samples that must exist at
each leaf.
n_estimators
The number of trees in the
forest.
max_features
The number of features to
consider when looking for
the best split

Value
{1e-7,1e-6,1e-5,1e18}

{2,5,7,18}

{1,3,5,7,18}

{1000}
{10,20,30,40,50,60,70,80,90}

Table 4.4 RF hyperparameters

cancer cell line and is numerical. It notes that the cell line's genomics features were not used
in model training to compare different chemical representations' performance directly.
The data were randomly split into training/development and testing sets. The
training/development set included 124 chemicals and was used for determining optimal
hyperparameters using leave-one-out cross-validation. After the hyperparameters were
determined, an independent hold-out test set that included 20 chemicals was used to evaluate
the performance of the trained model. The performance metric is Pearson's correlation
coefficient between actual and predicted AUC of anti-cancer drugs.
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Results

Figure 4.2 The average of Pearson’s correlation coefficients (top) and standard deviation for each
fingerprint and each algorithm across all 7 cell lines, respectively.

Figure 4.3 The average of Standard deviation across all algorithms
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Figure 4.4 The average rank of each fingerprint across algorithms (top) and across cell lines
(bottom)
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I have evaluated the performance of five of the state-of-the-art algorithms (RF, RF_EXTR, SVR,
KNR, and XGB) with all possible combinations between seven cancer cell lines and fingerprint
representations of the chemical compounds. The seven cancer cell lines are the large intestine,
breast, endometrium, glioma, lymphoma, prostate, and leukemia.

As shown in Fig. 2, the LTIP representation clearly outperformed all other fingerprints on an
average regardless of the algorithm used. The best performance is achieved by LTIP trained with
RF_EXTR with a Pearson's Correlation Coefficient (PCC) of 0.58. It is about 75% higher than
the second-best performance by the ap2d fingerprint (PCC = 0.33). Furthermore, the standard
deviations of PCC of the LTIP are minor across cell lines (Fig. 3), compared with that of other
fingerprints. Also, the rank of LTIP is low compared to other fingerprints when comparing
across algorithms and cells. When comparing across cell lines LTIP was always the lowest rank
except with XGB where it was the third-lowest and the second-lowest when RF was run.
Comparing ranks across algorithms clearly shows that LTIP was always the lowest rank except
when the “breast” and “large intestine” cancer cell lines were used where it was the third-lowest
Thus, the performance of LTIP is robust. The robustness is a desirable property for a
computational method in real-world applications.

LTIP is complementary with other fingerprints
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Figure 4.5(a-e). Pearson’s correlation coefficients for each fingerprint, each algorithm, and each
cell line.

Although the performance of LTIP is more accurate and robust in general than the molecular
fingerprint, the best performing fingerprint varies significantly for different cancer cell lines and
algorithms, as shown in Fig. 4 (a – e). The results are summarized as follows.
Leukemia cell line. When applied to the Leukemia cell line, LTIP outperforms all other
fingerprints across all algorithms except the RF_EXTR and RF algorithms. KRFP and KRC
perform slightly better than the LTIP when using RF_EXTR and RF, respectively.

Prostate cancer cell line. The Prostate cancer cell line showed different results where LTIP
significantly outperforms all other fingerprints using all algorithms except the KNR algorithm.
When using the KNR algorithm, AP2D, AP2DC, and KRC outperform LTIP. Especially the
AP2D followed by KRC outperforms the LTIP with a noticeable margin.

45

Lymphoma cell line. LTIP significantly outperforms other fingerprints when applied to the
Lymphoma cancer line in all algorithms. The PCC of LTIP shows noticeable margins when
compared with those of other fingerprints.

Glioma cell line. Although the SSFP, MACCS, KRC, and AP2D fingerprints outperform LTIP
when using the XGB algorithm, LTIP has shown comparable PCC. LTIP outperforms all
fingerprints using the rest of the algorithms.

Endometrium cancer cell line. When applied to the Endometrium cancer cell line, the best
performing fingerprints are AP2DC, KRFP, KRFP, LTIP, and LTIP for SVR, XGB, RF,
RF_EXTR, and KNR, respectively.

Breast cancer cell line. LTIP fails to outperform all other fingerprints in all algorithms. The best
performing fingerprints are AP2DC, AP2D, AP2D, KRC, and AP2D for SVR, XGB, RF,
RF_EXTR, and KNR, respectively. It appears that atom pair-based fingerprints, including AP2D
and AP2DC, are the winner.

Large intestine cancer cell line. LTIP fails to outperform all other fingerprints in all algorithms.
However, not a single fingerprint dominates the best performer. The best performing fingerprints
are AP2DC, MACCS, KRFP, KRFP, and ESFP for SVR, XGB, RF, RF_EXTR, and KNR,
respectively.
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Furthermore, the correlations between the predictions using the LTIP feature and those using
conventional fingerprints are weak, as shown in Fig. 5. The low R-squared values and high Pvalues (all > 0.05) suggest that LTIP complements chemical fingerprints.

Figure 4.6 The Pearson’s correlation coefficients (top) and corresponding p-values (bottom)
between the predicted AUCs obtained from the LTIP and those from KRFP.

I further showed the vital complementary feature of LTIP using linear regression. I built linear
models by fitting a straight line considering each fingerprint prediction data as the dependent
variable and the LTIP predictions as the independent variables. The linear models will minimize
the least-squares errors between each fingerprint prediction and LTIP prediction. I used Rsquared results to evaluate each linear model individually. The R-squared will measure how
close the predicted data are to the fitted regression line. It is also known as the coefficient of
determination. It determines how much percentage of the response variable, which is fingerprints
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predictions, variation is explained by a linear model built using LTIP predictions as independent
features. Generally, the higher the R-squared values, the better the model fits the data :
𝑅) = 1 −

𝑢𝑛𝑒𝑥𝑝𝑙𝑎𝑛𝑖𝑒𝑑 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛
𝑇𝑜𝑡𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛

∑#!%& 𝑦!
𝑦Ÿ =
𝑛

− − 𝑡ℎ𝑒 𝑚𝑒𝑎𝑛 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑣𝑎𝑙𝑢𝑒 , 𝑦! 𝑖𝑠 𝑡ℎ𝑒 𝑎𝑐𝑡𝑢𝑎𝑙 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑣𝑎𝑙𝑢𝑒
𝑜𝑓 𝑖𝑛𝑠𝑡𝑎𝑛𝑐𝑒 𝑖 .

𝑡𝑜𝑡𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 = 𝑒𝑥𝑝𝑙𝑎𝑛𝑖𝑒𝑑 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 + 𝑢𝑛𝑒𝑥𝑝𝑙𝑎𝑛𝑖𝑒𝑑 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛
#

𝑡𝑜𝑡𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 = 2(𝑦! − 𝑦Ÿ))
!%&

𝑓! = 𝑚𝑥 + 𝑏 − − 𝑡ℎ𝑒 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑏𝑦 𝑡ℎ𝑒 𝑙𝑖𝑛𝑒𝑎𝑟 𝑚𝑜𝑑𝑒𝑙 . x ℎ𝑒𝑟𝑒 𝑖𝑠 𝑡ℎ𝑒 𝑓𝑖𝑡𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒
𝑤ℎ𝑖𝑐ℎ 𝑖𝑠 𝑡ℎ𝑒 𝐿𝑇𝐼𝑃 𝑣𝑎𝑙𝑢𝑒.
#

𝑒𝑥𝑝𝑙𝑎𝑛𝑖𝑒𝑑 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 = 2(𝑦Ÿ − 𝑓! ))
!%&

#

𝑢𝑛𝑒𝑥𝑝𝑙𝑎𝑛𝑖𝑒𝑑 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 = 2(𝑦! − 𝑓! ))
!%&

𝑡ℎ𝑒𝑛,
𝑅) = 1 −

(𝑡𝑜𝑡𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 − 𝑒𝑥𝑝𝑙𝑎𝑛𝑖𝑒𝑑 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 )
𝑒𝑥𝑝𝑙𝑎𝑛𝑖𝑒𝑑 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛
=
𝑡𝑜𝑡𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛
𝑡𝑜𝑡𝑎𝑙 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛
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In each figure below, I show the resultant linear models for each fingerprint prediction (y-axis)
when I fitted against LTIP (x-axis). I also showed tables showing R-squares and p-values for
some of the fitted linear models. The plots clearly show very low 𝑅) and high residuals values
(unexplained variations) of the fitted models which suggest that the correlations between LTIP
and other fingerprints are very low.

The plots clearly show that models, represented by explained portion (the linear relation), have
low predictive power. The predictive variables are not catching the explanatory information
which has leaked to the residual errors. The models suggest further that LTIP and other
fingerprints complement each other. Concatenations of both LTIP and other fingerprints could
improve the results over the ones achieved by LTIP which I show in the next section.
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Figure 4.7.1 R-squared results for MACCS
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Figure 4.7.2 R-squared results for KRFP
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Figure 4.7.3 R-squared results for AP2D
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R-Squared

P_value

Algorithm:svr/Target:large intestine

0.0346600724613

0.431934772383

Algorithm:xgb/Target:large intestine

0.336132557081

0.00737552893067

Algorithm:rf/Target:large intestine

0.2313306382

0.0318063738352

Algorithm:rf_extr/Target:large intestine

0.193599325456

0.0522104317646

Algorithm:knr/Target:large intestine

0.0948442011701

0.186510716256

Algorithm:svr/Target:breast

0.00538736902111

0.758441403085

Algorithm:xgb/Target:breast

0.268140652512

0.0193545479749

Algorithm:rf/Target:breast

0.34090760344

0.00687329450164

Algorithm:rf_extr/Target:breast

0.663235280887

1.23857379364E-05

Algorithm:knr/Target:breast

0.00508939151969

0.765031641973

Algorithm:svr/Target:endometrium

0.0517085670889

0.334958982757

Algorithm:xgb/Target:endometrium

0.111301260232

0.150579809256

Algorithm:rf/Target:endometrium

0.138265225486

0.106452117365

Algorithm:rf_extr/Target:endometrium

0.0505374122121

0.340641174804

Algorithm:knr/Target:endometrium

0.00373990670749

0.797856817412

Algorithm:svr/Target:glioma

0.0215591613457

0.536755189575

Algorithm:xgb/Target:glioma

0.000406831171382

0.932735853414

Algorithm:rf/Target:glioma

0.0924536380031

0.192449037329

Algorithm:rf_extr/Target:glioma

0.00404304757784

0.789992808971

Algorithm:knr/Target:glioma

0.0324913225078

0.446971037783

Algorithm:svr/Target:lymphoma

0.0290920927501

0.472162436832

Algorithm:xgb/Target:lymphoma

0.173635979408

0.067595295438

Algorithm:rf/Target:lymphoma

0.130121742368

0.118175450477

Algorithm:rf_extr/Target:lymphoma

0.00834464851926

0.701702615096

Algorithm:knr/Target:lymphoma

0.0157023418734

0.59861191729

Algorithm:svr/Target:prostate

0.000886415711861

0.900839117397

Algorithm:xgb/Target:prostate

0.0200256924875

0.551763475263

Algorithm:rf/Target:prostate

0.352620567689

0.00577135794648

Algorithm:rf_extr/Target:prostate

0.43442562673

0.00157306989744

Algorithm:knr/Target:prostate

0.00321649493487

0.812274579573

Algorithm:svr/Target:leukemia

1.34587034934E-05

0.987752891547

Algorithm:xgb/Target:leukemia

0.0925059850269

0.192316835811

Algorithm:rf/Target:leukemia

0.123254159606

0.129076634676

Algorithm:rf_extr/Target:leukemia

0.1496087032

0.0920430126947

Algorithm:knr/Target:leukemia

0.00621709691065

0.74107403583

Table 4.5 Full R-Squared and P_values results
between MACCS and LTIP
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R-Squared

P_value

Algorithm:svr/Target:large intestine

0.0184045787633

0.568482808996

Algorithm:xgb/Target:large intestine

0.067605555805

0.268246639674

Algorithm:rf/Target:large intestine

0.0604748962136

0.295968888273

Algorithm:rf_extr/Target:large intestine

0.0434163685115

0.378007450567

Algorithm:knr/Target:large intestine

0.00187810411273

0.856042122192

Algorithm:svr/Target:breast

0.000852884784471

0.902724017651

Algorithm:xgb/Target:breast

0.115308089926

0.142986157766

Algorithm:rf/Target:breast

0.0999433366649

0.174492292788

Algorithm:rf_extr/Target:breast

0.0746408365662

0.243825954562

Algorithm:knr/Target:breast

0.093260426235

0.190422388283

Algorithm:svr/Target:endometrium

0.145678540129

0.0968000813713

Algorithm:xgb/Target:endometrium

0.112103248541

0.14902697339

Algorithm:rf/Target:endometrium

0.106487461089

0.160263190269

Algorithm:rf_extr/Target:endometrium

0.00506724607773

0.765529669499

Algorithm:knr/Target:endometrium

0.0338779012225

0.437270929287

Algorithm:svr/Target:glioma

0.174255518306

0.0670577082566

Algorithm:xgb/Target:glioma

0.00262279409438

0.830215420981

Algorithm:rf/Target:glioma

0.00773379132908

0.712365920565

Algorithm:rf_extr/Target:glioma

0.0120364350999

0.645198100611

Algorithm:knr/Target:glioma

0.0067996725506

0.729630409275

Algorithm:svr/Target:lymphoma

0.190634769319

0.0542592663439

Algorithm:xgb/Target:lymphoma

0.110764130784

0.15162925135

Algorithm:rf/Target:lymphoma

0.0681191056608

0.266371092779

Algorithm:rf_extr/Target:lymphoma

0.135107851559

0.110851196924

Algorithm:knr/Target:lymphoma

0.00891772359726

0.69209442473

Algorithm:svr/Target:prostate

0.000934837531129

0.898179850359

Algorithm:xgb/Target:prostate

0.00141325645212

0.874967452003

Algorithm:rf/Target:prostate

0.0306922178273

0.460042302558

Algorithm:rf_extr/Target:prostate

0.0737924619465

0.24663095936

Algorithm:knr/Target:prostate

0.0150609019635

0.606238744797

Algorithm:svr/Target:leukemia

0.110561094559

0.15202793018

Algorithm:xgb/Target:leukemia

0.0248764599197

0.5066159054

Algorithm:rf/Target:leukemia

0.0266863966006

0.491344887884

Algorithm:rf_extr/Target:leukemia

0.113565286922

0.146238914149

Algorithm:knr/Target:leukemia

0.0437912230509

0.375909851096

Table 4.6 Full R-Squared and P_values
results between KRFP and LTIP
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R-Squared

P_value

Algorithm:svr/Target:large intestine

0.000260082541555

0.946197557561

Algorithm:xgb/Target:large intestine

0.168756542877

0.0719788269242

Algorithm:rf/Target:large intestine

0.156619665145

0.0841264055117

Algorithm:rf_extr/Target:large intestine

0.311296691773

0.0105774314761

Algorithm:knr/Target:large intestine

0.0351582076412

0.428585542935

Algorithm:svr/Target:breast

0.185345695155

0.0581087266764

Algorithm:xgb/Target:breast

0.28001009179

0.0164334656995

Algorithm:rf/Target:breast

0.194456756372

0.0516318749907

Algorithm:rf_extr/Target:breast

0.0896244357886

0.199743049607

Algorithm:knr/Target:breast

0.142789188676

0.10045309974

Algorithm:svr/Target:endometrium

0.164569700442

0.0759608303651

Algorithm:xgb/Target:endometrium

0.0749104068403

0.242942291954

Algorithm:rf/Target:endometrium

0.132278302294

0.114949287194

Algorithm:rf_extr/Target:endometrium

0.23536001442

0.0301444952759

Algorithm:knr/Target:endometrium

0.199423072225

0.0484001135543

Algorithm:svr/Target:glioma

0.0436783818897

0.376539645003

Algorithm:xgb/Target:glioma

0.0170464498824

0.583243918741

Algorithm:rf/Target:glioma

0.102389247649

0.169023392042

Algorithm:rf_extr/Target:glioma

0.00788936904015

0.709606267012

Algorithm:knr/Target:glioma

0.195151254574

0.0511677831378

Algorithm:svr/Target:lymphoma

0.000406352003803

0.932775391247

Algorithm:xgb/Target:lymphoma

0.280627241708

0.0162934408228

Algorithm:rf/Target:lymphoma

0.180103427914

0.0621840804591

Algorithm:rf_extr/Target:lymphoma

0.311221414569

0.0105888357403

Algorithm:knr/Target:lymphoma

0.25064972006

0.0245532979667

Algorithm:svr/Target:prostate

0.181517794154

0.0610580560144

Algorithm:xgb/Target:prostate

0.164620503946

0.075911242102

Algorithm:rf/Target:prostate

0.197844551747

0.0494056465902

Algorithm:rf_extr/Target:prostate

0.0156985281482

0.598656681348

Algorithm:knr/Target:prostate

0.0145215218946

0.612810146518

Algorithm:svr/Target:leukemia

0.105259051809

0.162837532148

Algorithm:xgb/Target:leukemia

0.267058026545

0.0196437801364

Algorithm:rf/Target:leukemia

0.190621067347

0.054268913362

Algorithm:rf_extr/Target:leukemia

0.212948705112

0.0405511821002

Algorithm:knr/Target:leukemia

0.0693009817491

0.262112486036

Table 4.7 Full R-Squared and P_values
results between AP2D and LTIP
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Performance improvement by combining LTIP with molecular fingerprints
Since LTIP complements other fingerprints, combining LTIP with other fingerprints may
improve individual performance. Therefore, I tested the performance of machine learning models
by concatenating the LTIP feature with other fingerprint features. Specifically, I used the feature
sets for AP2D, MACCS, and KRFP fingerprints. New training sets are specified as AP2D+LTIP,
MACCS+LTIP, and KRFP+LTIP. The same concatenation process was applied to the testing
sets. The results varied across different kinds of concatenation. The results of comparing the
concatenated (AP2D+LTIP, MACCS+LTIP, and KRFP+LTIP), non-concatenated fingerprints
(MACCS, AP2D, KRFP), and LTIP are shown in
Fig. 6a and 6b. Because of the high dimension of the concatenated feature vector, only RF and
RF_EXTR were tested, and their results are summarized as follows.

Large intestine cancer cell line. When the RF_EXTR was used, AP2D+LTIP and
MACCS+LTIP outperformed LTIP with a noticeable margin. KRFP+LTIP showed comparable
results to LTIP. All concatenated fingerprints outperformed the non-concatenated counterparts.
The results with RF were a bit different. All concatenated fingerprints outperformed the
individual counterparts except MACCS that outperformed its concatenated counterpart
(MACCS+LTIP)

Breast cancer cell line. Using the RF_EXTR algorithm, AP2D+LTIP outperformed all
concatenated and individual fingerprints. All the concatenated ones outperformed the individual
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fingerprints with a noticeable margin, primarily when KRFP+LTIP was used. When the RF
algorithm was used, all concatenated fingerprints outperformed the non-concatenated
counterparts except AP2D, which outperformed its concatenated counterpart (AP2D+LTIP).

Endometrium cancer cell line. Using the RF_EXTR algorithm, MACCS+LTIP outperformed all
concatenated and individual fingerprints with a noticeable margin. All the concatenated ones
outperformed the non-concatenated fingerprints with a noticeable margin, especially
KRFP+LTIP and AP2D+LTIP. Using the RF algorithm, MACCS+LTIP and AP2D+LTIP
outperformed LTIP, while KRFP+LTIP showed comparable results. MACCS outperformed all
concatenated and individual fingerprints with a noticeable margin.

Glioma cell line. Using the RF_EXTR algorithm, all concatenated ones outperformed their
counterparts and the LTIP. Using the RF algorithm, while MACCS+LTIP and AP2D+LTIP
showed comparable results, they outperformed all concatenated and individual fingerprints with
a noticeable margin. All concatenated fingerprints outperformed the individual molecular
fingerprints and the LTIP.

Lymphoma cell line. Using the RF_EXTR & RF algorithm, all concatenated fingerprints
outperformed the individual molecular fingerprints and the LTIP.

Prostate cancer cell line. Using the RF_EXTR algorithm, AP2D+LTIP outperformed its
individual counter fingerprint (AP2D) with a noticeable margin. Although KRFP+LTIP
outperformed KRFP, it showed a low Pearson's correlation coefficient. MACCS+LTIP has
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outperformed all concatenated and individual molecular fingerprints and the LTIP with a
noticeable margin using the RF algorithm.

Leukemia cell line. Using the RF_EXTR algorithm, MACCS+LTIP and AP2D+LTIP slightly
performed better than their counterparts. Using the RF algorithm, all the individual fingerprints
have outperformed their concatenated counterparts.

In summary, the concatenation of LTIP with molecular fingerprints has improved its predictive
performance in most cases when the RF_EXTR algorithm is used for the model training. It may
be because that RF_EXTR performs better in handling extremely high-dimensional data than the
RF.
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Figure 4.8 (a-b). The performance comparison of the concatenated features (AP2D+LTIP,
MACCS+LTIP, and KRFP+LTIP) and individual fingerprints (MACCS,AP2D,KRFP, and LTIP) using
(Top) RF and (bottom) RF_EXTR algorithm, respectively.

Discussion

In this proof-of-the-concept study, I have shown that LTIP is more accurate and robust in general
than conventional chemical fingerprints in the predictive modeling of bioactivities regardless of
the algorithm being used or the target being tested. There are several advantages of LTIP
compared with chemical fingerprints. First, LTIP embeds the genome-scale target binding
profile and fills in one of the missing links between chemical structure and bioactivity. Second,
the number of features in LTIP is low compared to most of the chemical fingerprints; thus, more
robust machine learning models can be built. Third, the complementarity of LTIP suggests that
LTIP combined with other fingerprints may improve the predictive performance for specific
targets, which is seen for many of the cancer cell lines. Fourth, the high predictive power
of LTIP suggests that it will present a better similarity measure between chemicals, which suffers
from activity cliffs when the Tanimoto coefficient of chemical fingerprints is used.

Although LTIP shows promising results in most cases, it does not perform well compared with
the chemical fingerprints. The performance of LTIP can be improved in several directions.
Technically, the accuracy of LTIP depends on both the quality of chemical genomics data used
and the underlying algorithms for learning latent factors. Besides, the REMAP algorithm will not
learn non-linear mapping functions, which is a clear disadvantage. With the recent advancements
in technologies, implementing LTIP and the rich available genomics information on neural
networks could be very promising for future discoveries.
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RF
SVR
XGB
KNR
RF_EXTR
Average

ap2dc

ap2d

extended esfp

krc

krfp

maccs pcfp

ssfp

LTIP

0.104
0.35
0.09
0.29
0.14
0.1948

0.44
0.35
0.43
0.43
0.33
0.396

0.22
0.203
0.23
0.15
0.19
0.1986

0.32
0.34
0.29
0.43
0.26
0.328

0.24
0.22
0.28
0.102
0.13
0.1944

0.46
0.14
0.42
-0.01
0.29
0.26

-0.04
-0.08
0.04
0.08
0.06
0.012

0.03
-0.04
0.104
-0.04
0.06
0.0228

0.53
0.53
0.43
0.52
0.58
0.518

maccs
0.22
0.24
0.21
0.26
0.36
0.258

pcfp
0.21
0.17
0.204
0.204
0.28
0.2136

ssfp
0.15
0.11
0.14
0.26
0.33
0.198

LTIP
0.12
0.09
0.16
0.18
0.11
0.132

0.27
0.16
0.17
0.201
0.11
0.1822

Table 4.8 Average Pearson’s correlation coefficient across all cell lines.
The best value for each algorithm is highlighted with bold.

ap2dc
RF
0.14
SVR
0.27
XGB
0.18
KNR
0.09
RF_EXTR 0.22
Average
0.18

ap2d
0.25
0.23
0.19
0.202
0.16
0.2064

extended
0.29
0.24
0.24
0.29
0.27
0.266

esfp
0.19
0.201
0.14
0.26
0.28
0.2142

krc
0.21
0.14
0.27
0.17
0.28
0.214

krfp
0.23
0.16
0.21
0.22
0.18
0.2

Table 4.9 The standard deviation of Pearson’s Correlation coefficient across all cell lines.

The best value for each algorithm is highlighted with bold.
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Chapter 5
Learning the protein language
Bidirectional Encoder Representations from Transformers (BERT) is a technique for NLP pretraining developed by Google. The main advantage of BERT is that its ability to learn
dependencies between the sequence tokens. The sequence can be either text or protein
molecules. BERT will apply bi-directional attention models, which will create more robust
sequence representations of the context and tokens relationships. BERT hidden layers
representations can be used for transfer learning. Precisely, BERT can be used as a feature
extraction model where the learned representation knowledge of protein structures can be shared
and used on other models. Protein sequences will be passed to the pre-train BERT model, then
extract the activations from one or more layers (one or more of the last layers, since the features
associated with these layers' activations, are far more complex and include more context) of this
pre-trained model. The length of the hidden layers is equal to the input layer, which is protein
sequence tokens. Precisely, there is a one-to-one correspondence between the input layer and the
output of the hidden layers.

CGKronRLS Algorithm
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Machine learning in bioinformatics domains mainly studies the relationships between structural
objects such as drugs and proteins. These relationships can be naturally represented as graphs
where nodes represent drugs and proteins. The drug-protein pair affinity is the edge label. These
labels can construct what is called the adjacency matrix of the graph. Naturally, the given
training set (𝑑, 𝑡, 𝑦) where 𝑑 is the drug and start vertex, 𝑡 is the protein (end vertex) and is the
label of the edge or the affinity, can be looked at as a bipartite graph that is not fully connected.
The training set can be looked at as input pairs of drugs and proteins with their associated label.
Each drug and protein in each pair will have its feature representation. Parts of each instance
pair, namely drug or protein features, may appear in other instances in the training set. Such
paired training sets can be found in recommender systems where users may be associated with
several products or in information retrieval where the pairs will be queries and data to be
retrieved. Specifically, each vertex on one set is not connected to all vertices on the other set of
the graph. The goal will be to predict missing possible edges between both sets (drugs, proteins).
More than one scenario can exist in this case. Precisely, we have a new pair drug-protein pair
(𝑑, 𝑡), and we want to predict the label of its possible edge. The first scenario will happen when
both the drug and protein of the new pair exist in the training sets and have edges to other
proteins and drugs, and the goal will be to predict the label of the edge. Recommender systems
model the same idea where the dataset includes edges between different pairs of (𝑢𝑠𝑒𝑟, 𝑖𝑡𝑒𝑚)
and the goal is to predict the label of an entirely new pair (𝑢𝑠𝑒𝑟, 𝑖𝑡𝑒𝑚). Precisely, the idea
behind recommender systems where we have user-product data, and the goal will be to predict if
the user will buy a new product that it has not seen before ( the edge). The second case will be
that the protein exists in the training set, but the drug is not part of any edges in the original
training set graph. The third case will be that when the drug appears in some edges in the
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original training graph, the protein that I want to predict its affinity does not appear in the
training set of the graph. The last two scenarios represent a multi-target prediction
problem. The fourth and last scenario is when neither the drug nor the protein appears in the
training set of the graph, which represents what is called zero-shot learning problem where the
model generalizes the training set of the partially observed graph in hand to a new problem of
entirely new drug and new protein that has not been seen before. Both training and testing sets
are entirely disjoint. Formally,
Assuming that 𝒟 is the set of all possible drugs and 𝔗 is the set of all possible target, and 𝑑 and
𝑡 are any drug and targets respectively I can summarize the above cases :

1st case : 𝑑 ∈ 𝒟 𝐴𝑁𝐷 𝑡 ∈ 𝔗
2nd case : 𝑑 ∉ 𝒟 𝐴𝑁𝐷 𝑡 ∈ 𝔗
3rd case : 𝑑 ∈ 𝒟 𝐴𝑁𝐷 𝑡 ∉ 𝔗
4th case: 𝑑 ∉ 𝒟 𝐴𝑁𝐷 𝑡 ∉ 𝔗

Precisely the goal is to make the original bipartite graph fully connected; in other words, each
vertex in each vertex set, 𝒟 & 𝔗 , will be connected to all vertices in the other set. The training
data features can be represented as the Kronecker product of the drug and protein kernel
functions, and the target will be the affinity. So, each instance in the final training dataset will be
an edge kernel resulting from the drug and protein kernel Kronecker product, while the target
will be the affinity. The number of features equal to the original number of input drug-protein
pairs included in the final training set will be so high that the memory and CPU requirement will
grow quadratically with respect to the graph's number of vertices. The pair-input problem can be
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resolved using any kernel-based algorithm like the regularized least square, RLS. With the drug
and protein kernels' tensor product, RLS can accelerate arriving at a closed-form solution,
especially when using the vec-tric, which avoids the expensive computation of the tensor
product. The proposed algorithm can also be optimized further by using the sparsity of the
training dataset, specifically, utilizing the fact that not all possible pairs of 𝒟 & 𝔗 are known
and included in the training dataset. If the training set is complete, in other words, the bipartite
graph is fully connected, and there is a label for every possible drug and protein pair(𝑑, 𝑡), a
closed-form solution can be found for any new instance. While the training set is incomplete and
there are missing pair labels, the algorithm will try to find the best solution using iterative
optimization algorithms like conjugate gradient, CG.

Assuming that there are 𝑚 drug-protein pairs (𝑑, 𝑡) included in the training set, the goal is to
build a predictive model associating any pair (𝑑, 𝑡) to its affinity 𝑦. Formally, we are looking to
build a function ℱ: (𝒟 × 𝔗) → ℛ that function will learn the affinities related to the input
data pairs. I will use a special case of the known regularized least square algorithms, RLS,
namely KronRLS which will incorporate the Kronecker product kernel. RLS algorithms
generally minimize the following:

𝑎𝑟𝑔𝑚𝑖𝑛
ℱ ∈ ℋ

𝑅(ℱ)

+

𝜆 ‖ℱ‖)

ℱ is the model learned function , 𝜆 ‖ℱ‖) is the regularization term and 𝑅(ℱ) is the empirical
risk.
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specifically , I need to minimize the following loss function :

)
)
ℒ(ℱ) = ∑(
!%&(𝑦! − ℱ(𝑥! ) ) + 𝜆‖ℱ‖S

Where ,
¨ ‖ℱ‖)S is the norm of the learned predicting function ℱ

measured in the Hilbert space

associated to the kernel function k.
¨ 𝜆 is a strictly positive regularization parameter that balances between how much the
model will fit the training data accurately (low bias) and how much it can better
generalize to predict unseen pairs well (low variance).
¨ 𝑦! is the original affinity of the drug-target pair 𝑥! .
¨ 𝑘 is the composite similarity measure kernel function or specifically the Kronecker
product function of 𝑘M ,the drug kernel function ,and 𝑘3 , the target kernel function . the
Kronecker product kernel of two input drug-protein pairs 𝑥! (𝑑! , 𝑡! ) and 𝑥" f𝑑" , 𝑡" g can
be given as :
𝑘f𝑥! , 𝑥" g = 𝑘M f𝑑! , 𝑑" g 𝑘3 f𝑡! , 𝑡" g
The final training set based on kernel-based pairs similarities can be formally stated as :
𝑎!
𝑦!
𝑘(𝑥! , 𝑥! ) 𝑘(𝑥! , 𝑥" ) 𝑘(𝑥! , 𝑥# ) … . 𝑘(𝑥! , 𝑥$ )
.
!
*! * = ! . *
…..
….
𝑦$
𝑘(𝑥$ , 𝑥! ) 𝑘 (𝑥$ , 𝑥" ) 𝑘(𝑥$ , 𝑥# ) … … … … … 𝑘 (𝑥$ , 𝑥$ ) 𝑎$
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The representer theorem guarantees that the optimal solution is of the form:

ℱ(𝑥) = ∑(
!%& 𝑎! 𝑘(𝑥, 𝑥! )

where ,

¨ 𝑎 ∈ ℛ ( is the vector of dual coefficients that the model will learn iteratively and can be
found by solving the following system equations:

(Κ + 𝜆Ι)𝒶

=

𝑦

𝒶, 𝑦 are of 𝑚 × 1 dimensions . Ι(×( is the identity matrix . Κ (×( is the Kronecker product
matrix of 𝑘M and 𝑘3 matrices and will measure the similarity of any two drug-protein pairs.
Using the Kronecker product as a similarity measure between input pairs suggests that
information is encoded in the similarity between observations, with more similar observations
expected to have more similar outcomes. The final prediction formula above
evaluate the outcome linearly in the similarities of the test pair to each input pair in the training
set, which means that the closer the test pair to the input pair, the more influence it will have on
the final prediction.
Let,
𝑘M = V⋀V3 be the eigen-decomposition of the kernel matrix 𝑘M where V orthogonal matrix
consisting of the eigenvectors and ⋀ is the diagonal matrix containing the eigenvalues of 𝑘M .

𝑘3 = UΩU 3 be the eigen-decomposition of the kernel matrix 𝑘3 where U orthogonal matrix
consisting of the eigenvectors and Ω is the diagonal matrix containing the eigenvalues of 𝑘3 .
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The model parameters vector can be found using:

𝒶 = 𝑣𝑒𝑐(UCV T ) , C is the matrix where the following holds:

𝑣𝑒𝑐(C) = (⋀⨂ Ω + 𝜆Ι)R& 𝑣𝑒𝑐(U T Y T V), Y ∈ ℛ |V|×|𝔗|

If the training input drug-protein pairs (𝑑, 𝑡) is complete I can use any solver to find a closed
form solution . Concretely , if there is an affinity data for each possible single pair in |𝐷| × |𝔗| ,
i.e the bipartite graph is fully connected , I can find the function ℱ(𝑥) that will converge to the
actual targets. Due to the incompleteness of the input pairs, I must resort to other optimization
solutions as conjugate gradient CG , hence the CGKronRLS algorithm. Conjugate gradient is an
optimization technique that iteratively solves the following system of equation where Α is
strictly positive-definite and symmetric matrix:

Αx = b
Using the Roth’s column lemma; ”Vec-trick” (15)

(Ν '

⨂

M)𝑣𝑒𝑐(Q) = 𝑣𝑒𝑐(MQN) , where M, Q and N are any matrices and 𝑣𝑒𝑐 is the

vectorization operator which stacks the columns of any matrix into a vector.

Solving the above system of equations is equivalent to finding the minimum of the quadratic
form below if A is symmetric and strictly positive definite:
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𝑓(𝑥) =

1 T
𝑥 Αx + 𝑏 T x
2

Where ,

Α = 𝐴'
𝑥'Α 𝑥

− −𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑖𝑐

> 0 ∀𝑥 ≠ 0 − − 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑑𝑒𝑓𝑖𝑛𝑖𝑡𝑒

As the derivative of 𝑓(𝑥) is :

𝑓 X (𝑥) = Αx − b

The steepest descent gradient method starts by guessing a starting point and then taking steps
toward the negative gradient towards the global minimum using a line search method. Then
repeat the same steps at the new resulting point till arriving at the global minimum. Conjugate
gradient improves the steepest descent gradient by avoiding repeated steps. Specifically, it takes
steps in Α orthogonal to the gradient direction at the current point on the optimized graph. Each
subsequent gradient vector is orthogonalized against all the previous ones. Two vectors are Α
orthogonal if :

𝑑"3 Α𝑑! = 0

The conjugate gradient will take fewer steps than the steepest gradient algorithm and will never
do or undo any optimization steps in the previous iteration. It will converge in steps equal to the
number of model parameters in our case length of vector 𝒶 , which is a considerable advantage,
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especially when dealing with models with a high number of parameters as in the drug-protein
case.

I have used Random Forest (RF), XGBoost(XGB) CGKronRLS(A), and CGKronRLS(C) to test
and compare our proteins list. Where CGKronRLS(A) refers when using the CGKronRLS
algorithm when both the drug and the protein of the testing pair exist in the training set(1st case)
while CGKronRLS(C) refers to the case when only the protein exists in the training set(3rd
case). I used Geary, SOCN, QSO, Moran, APAAC, BertSeq, DescSc, MoreauBroto, and ProtFP
are Sequence-derived structural and physicochemical descriptors representing and distinguishing
proteins or peptides of different structural, functional, and interaction profiles by exploring their
prominent composition correlations and distributions of the constituent amino acids and their
structural and physicochemical properties.

BertSeq is the outcome of the internal hidden layers of the DISAE ALBERT-based model.
Proteins that do not have assigned drugs are called orphan proteins or unlabeled proteins.
Developing sequence-based machine learning algorithms for de-orphanization could answer
many questions, e.g., evolutionarily related. DISAE, Distilled Sequence Alignment Embedding
(3), is a self-supervised pre-training-fine-tuning model that will utilize the power of BERT or,
specifically, a modified BERT model to overcome significant systems limitations. DISAE
is an algorithm to annotate remote orphan proteins. DISAE will incorporate the rich biological
information contents currently existing in databases to predict ligand affinities. DISAE will work
in two phases: pre-train then fine-tuning.
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The pre-training phase will distill the original un-annotated Pfam protein sequences into an
ordered list of triplets or singlets to build a self-supervised representation learning model using
the masked language modeling (MLM) approach and sentence order prediction (SOP). The input
to the fine-tuning phase will be the protein representation from the self-supervised pre-training
phase and the fingerprints representing the chemicals. DISAE uses ALBERT to allow for system
growth while achieving good performance. Specifically, a pre-trained-fine-tuned model is used
in ALBERT to address the challenge of labeling and identifying novel proteins on a genomescale. ALBERT is a modified BERT model to balance the need to improve performance by
increasing the model size and CPY/TPU limitations. The balance is achieved through parameter
reductions to allow for faster and low memory consumption BERT models. The first parameter
reduction is made through matrix factorization by feeding the one-hot vector representing the
word to a low dimensional space which can then be projected to the hidden size space. The
process above will significantly reduce the size of the parameter of the hidden layer and allow it
to grow regardless of the size of the hidden layer without significantly increasing the embedding
matrix size. ALBERT proposes a factorization technique that first learns a relatively small
hidden dimension (e.g., 128, which is the default) per word and then learns to a separate function
to project this to the transformer’s encoders' hidden dimension (e.g., 1024). ALBERT uncouples
the hidden layer's size from the embedding size, thus increasing the hidden size of the attention
units of encoder layers without adding that many weights to the model. Specifically, assuming
that the vocabulary size is 𝑉 ,the embedding size is 𝐸 and the hidden size of the multi-head
attention layer is 𝐻 ALBBERT reduces the parameters size of the hidden size from 𝑂(𝑉 × 𝐻)
(in BERT 𝐸 = 𝐻) to 𝑂(𝑉 × 𝐸 + 𝐸 × 𝐻) which is a significant reduction. The second
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reduction comes from the cross-layers sharing of the parameters. Specifically, feed-forward and
attention layers parameters can be shared, allowing
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more layers and increasing the depth of the encoder network without significantly increasing the
size of the parameter’s matrix.
Another improvement that ALBERT adds is the use of sentence order prediction, SOP, as a pretraining task instead of BERT's next sentence prediction, NSP.

A negative example of NSP is created by swapping the next sentence with another one from a
different document than the first one. This sentence usually has a different topic, so it is easier
for the model to detect it. This is considered a weak task that will not capture the full contextdependent information within the sentences' tokens. In contrast, The SOP task is based on intersentence coherence, not the topic. Positive examples are created the same way as in the NSP
(two consecutive segments from the same document). Negative examples are also created by
taking two consecutive segments from the same document, flipping their order. This way, the
topic stays the same in both cases.

DISAE will employ a deep learning model to utilize the large corpus of unlabeled proteins to
build protein sequences that strongly represent its internal structure, functions, and relationships
with other proteins genome-wide. For our purposes, I will only use the pre-training protein
representations of the DISAE model. First, DISAE distills the original sequence into an ordered
list of triplets by excluding evolutionarily unimportant positions from a multiple sequence
alignment. The reason for distilling is removing noisy tokens by reducing the input sequence
length, thus requiring fewer parameters when training. Then long-range residue-residue
interactions are learned via the Transformer module in ALBERT. DISAE will employ a masked
language model during pre-training to generate the final protein representations which is the
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input to the fine-tuning phase. ~ 15% of the input tokens will be masked, and they will be
assumed as targets to be predicted or unknown. The distilled protein sequences which will be the
input to the pre-training model will be an ordered list of single amino acids or triplets of amino
acids which may contain gaps. Once processed by the pre-training phase, each protein will be
represented by a 210 x 312 matrix where each of the 210 triplets is 312 in length. This matrix
will be further compressed by the ResNet module (during the fine-tuning phase) into a 256
sequence.

A supervised model will be built in the fine-tuning phase to predict if a drug-protein pair will
bind together. Attentive pooling will be applied to both the pre-trained protein representation and
compound fingerprints. The goal of the pooling layer is to see how information from the input
pair will affect each other final representation. Two attention vectors will be created, regarded as
importance scores on different units in the input pairs. The two attention vectors are multiplied to
create a final vector that can be used as an input to the classifier. I used the ALBERT hidden
layer representation as protein features vectors, which I named (BertSeq),
in machine learning models and compare its predictive power with other proteins representation.

I used Random Forest and XGBoost as baseline algorithms to compare assess BertSeq prediction
power using the CGKronRLS. When using CGKronRLS, I used it specifically when both the
drug and the protein of the testing pair exist in the training set, setting A, (𝑑 ∈ 𝒟 𝐴𝑁𝐷 𝑡 ∈ 𝔗)
and when only the drug appeared in the training set while the protein is new,setting C, (𝑑 ∈
𝒟 𝐴𝑁𝐷 𝑡 ∉ 𝔗) . I used the same Input drug-protein pairs, which were separated randomly into
development, training, and testing folds, consistently in all algorithms during the experiment
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except setting C in the CGKronRLS algorithm. Setting C requires a particular setup before the
experiment, which requires that the testing fold include drug-protein pairs where proteins do not
appear in the training set, making it difficult to use the same development, training, and testing
folds used in RF, XGB, and CGKronRLS setting A . when creating the training, development,
and prediction folds for setting C, I have created a list of all proteins indexes and randomly split
them into three folds and used two folds for training and development and one fold for
predictions. Then I iterated over the list of all available drug-protein pairs, and if the protein in
the pair appears in the train-fold indexes list, then it is added to the train-dev dataset fold that
will be used during the training and development phase; otherwise, the pair is added to the
prediction fold. This way, all pairs in the prediction fold will have their proteins not included in
the training fold. Then the training fold was again split into three-fold where two folds were
used combined for training, and the remaining fold was used for choosing the best regularization
parameter. I have used two kernels𝑘M and 𝑘3 , which will measure the similarities ( cosine
similarity) between drugs and proteins' features, respectively. Extensive grid search was used
during the development phase using the development fold when running base algorithms RF and
XGB to find the best model parameters before the prediction phase. Development fold was also
used when running CGKronRLS for setting A and C to find the best regularization parameter
regparam. I used 200 iterations during the development phase of CGKronRLS for settings A and
C . Once the best regparam is chosen, I use that value to train the model, using both the
development and training folds for a full of 2500 iterations. I measured the Cindex and Pearson
values for the predicted results. Cindex, pairwise ranking accuracy, computes the relative
fraction of concordant (equivalent to the area under the ROC curve when predicted target ∈
{−1,1}. I noticed that Pearson results for most of the proteins keep increasing until they reached
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a maximum value at a certain number of iterations, where it starts to decrease again. Cindex
keeps on increasing as more iterations are done.

When creating the datasets for base algorithms, RF and XGB, drug and protein actual features
were concatenated together in training, development, and prediction folds. The target was the
affinity of each pair. Grid search was used to choose the best parameters for each algorithm
using the development phase.

𝐂𝐆𝐊𝐫𝐨𝐧𝐑𝐋𝐒 = (𝐗𝟏, 𝐗𝟐, 𝐥𝐚𝐛𝐞𝐥_𝐫𝐨𝐰_𝐢𝐧𝐝𝐬, 𝐥𝐚𝐛𝐞𝐥_𝐜𝐨𝐥_𝐢𝐧𝐝𝐬, 𝐫𝐞𝐠𝐩𝐚𝐫𝐚𝐦, 𝐘)
Where :
𝐗𝟏 Drug kernel matrix.
𝐗𝟐 Target kernel matrix.
𝐫𝐞𝐠𝐩𝐚𝐫𝐚𝐦 Model regularization parameter.
𝐘 affinity targets of drug-protein pairs.
𝐥𝐚𝐛𝐞𝐥_𝐫𝐨𝐰_𝐢𝐧𝐝s indexes row indexes of Y entries within 𝑋1.
𝐥𝐚𝐛𝐞𝐥_𝐜𝐨𝐥_𝐢𝐧𝐝s indexes of Y entries within 𝑋2

Comparing individual protein representations across different algorithms
Geary, when using the protein, it performed the best when using CGKronRLS(A), and it
outperformed all base algorithms and CGKronRLS(C). while XGB performed the lowest, RF
outperformed both XGB and CGKronRLS(C).

76

SOCN, when using the protein, it performed the best when using CGKronRLS(A), and it
outperformed all base algorithms and CGKronRLS(C). while RF performed the lowest, XGB
outperformed both RF and CGKronRLS(C).

QSO, when using the protein, it performed the best when using CGKronRLS(A), and it
outperformed all base algorithms and CGKronRLS(C). while RF performed the lowest, XGB
outperformed both RF and CGKronRLS(C).

Moran performed the best when using CGKronRLS(A), and it outperformed all base algorithms
and CGKronRLS(C). while XGB performed the lowest, CGKronRLS(C) outperformed RF.

APAAC performed the best when using CGKronRLS(A), and it outperformed all base
algorithms and CGKronRLS(C). while CGKronRLS(C) performed the lowest, RF performed
better than XGB.

BertSeq performed the best when using CGKronRLS(A), and it outperformed all base
algorithms and CGKronRLS(C). while RF performed the lowest, CGKronRLS(C) showed a
better performance than both base algorithms RF and XGB.

DescSc performed the best when using CGKronRLS(A), and it outperformed all base algorithms
and CGKronRLS(C). while CGKronRLS(C) showed the lowest performance, XGB
outperformed RF.
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MoreauBroto performed the best when using CGKronRLS(A). It outperformed all base
algorithms and CGKronRLS(C). while RF showed the lowest performance, CGKronRLS(C)
outperformed XGB.

ProtFP performed the best when using CGKronRLS(A). It outperformed all base algorithms and
CGKronRLS(C). While RF showed the lowest performance, XGB outperformed
CGKronRLS(C).

Comparing protein representations for each algorithm
Moran outperformed all algorithms, while ProtFP showed the lowest performance when using
the RF algorithm. MoreauBroto outperformed all algorithms, while Moran showed the lowest
performance when using the XGB algorithm. APAAC outperformed all algorithms, while
BertSeq showed the lowest performance when using the CGKronRLS(A) algorithm. BertSeq
outperformed all algorithms, while APAAC showed the lowest performance when using the
CGKronRLS(C) algorithm. While the CGKronRLS(A) algorithm showed higher Pearson results
than all algorithms, it showed along with CGKronRLS(C) some better results than base
algorithms especially when using BertSeq. The Kronecker product algorithm outperformed base
algorithms, mainly when used with setting A.
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Figure 5.2 CGKronRLS Results
Figure 5.2 CGKronRLS Results

Chapter 6
Conclusion and future directions

Although collaborative filtering is a robust predictive model that requires the least amount of
information about users and items, it has limitations. The extracted hidden, latent features cannot
be interpreted. Despite the rich information content of the latent features, the metadata cannot be
related to a known protein or drug properties. Also, collaborative filtering suffers from the cold
start problem when there is no data for completely unseen drugs or protein, producing biased
results. REMAP; hence LTIP accuracy will be affected by such limitations.
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Although LTIP has shown better in most cases, it does not perform well than chemical
fingerprints. The performance of LTIP can be improved along with several directions.
Technically, the accuracy of LTIP depends on the quality of chemical genomics data used and
thunder-lying algorithms for learning latent factors. With the advance in high-throughput
techniques, I expect a rapid increase in chemical and genomic space coverage. On the other
hand, the REMAP method used in the paper has limitations in representation learning since it can
only provide a linear mapping between the original feature space and the latent space. In this
regard, deep learning could be a promising approach to the LTIP coupled with the increasing
availability of chemical genomics data. Fundamentally, even if LTIP can accurately reconstruct
the genome-wide target interaction profile, it may not fill in the gaps between chemical structure
and bioactivity. The chemical-target interaction in vivo depends on the genetic and epigenetic
background of individuals. For example, a single nucleotide polymorphism may significantly
alter the chemical-target interaction. Thus, the incorporation of genomics information could be
critical for embedding chemicals in the context of precision medicine.

Furthermore, the molecular targets (e.g., proteins) do not work alone but interact with each other.
A gene interacting network view for the chemical representation may provide stronger
correlations between the chemical structure and the bioactivity than LTIP. It will be interesting
to use the same strategy for LTIP: to embed the biological pathway activity perturbed by
chemicals into their latent space. From the perspective of model building, the complementary
nature of LTIP with the chemical fingerprints suggests that other types of ensemble models the
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feature concatenation could improve the predictive modeling. The significant performance
diversity from different learning algorithms and fingerprints implies that case-based reasoning
could be an effective strategy to build the ensemble model underlying algorithms for learning
latent factors.

The CGKronRLS algorithm has shown promising results compared to other base algorithms, and
the pre-trained protein sequence BertSeq has performed the lowest among the rest of the proteins
used in the benchmark. BertSeq, when used with CGKronRLS, still outperformed other base
algorithms. Using BerSeq with CGKronRLS may not be the best approach in prediction. A finetuning layer may need to be added after pre-training the protein sequence. It will be interesting to
see such an experiment, we could mix LTIP and BERT representation together in one single
deep learning model. We first run the BERT representations for protein, run REMAP
to get the drug representation then concatenate both drug and protein representation in one single
downstream task which will compare CGkronRLS , XGB, RF.
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